Pending

Acute Compartment Syndrome of the Upper Extremity in Acquired Hemophilia A: A Case Report and Literature Review 8/27/2021
Physician practices in evaluation and treatment of patients with generalized joint hypermobility and bleeding 8/27/2021
Investigating Optimal Autologous Cellular Platforms for Prenatal or Perinatal Factor VIII Delivery to Treat Hemophilia A 8/27/2021
Mobile Health Technology for the Personalized Therapy of Hemophilia 8/27/2021
Novel Severe Hemophilia A Mouse Model with Factor VIII Intron 22 Inversion 8/27/2021
Predictors of the outcome of immune tolerance induction in patients with haemophilia A and inhibitors: The Brazilian Immune Tolerance (BrazIT) Study protocol 8/26/2021
Patients’ Perception of the Impact of Innovation on Hemophilia Care Management Organization: A Qualitative Study Protocol (INNOVHEMO Study) 8/26/2021
Impact of the Induction of Labor on Hemophilia Carriers and Their Newborn Infants 8/26/2021
Subcutaneous engineered factor VIIa marzeptacog alfa (activated) in hemophilia with inhibitors: Phase 2 trial of pharmacokinetics, pharmacodynamics, efficacy, and safety 8/25/2021
Effect of lower VWF and FXI levels on levonorgestrel IUS and endometrial ablation treatment success in heavy menstrual bleeding: An exploratory study 8/25/2021
Patient preferences in the treatment of hemophilia A: A latent class analysis 8/23/2021
Ultra-sensitive AAV capsid detection by immunocapture-based qPCR following factor VIII gene transfer 8/23/2021
Current therapeutic approaches in the management of hemophilia-a consensus view by the Romanian Society of Hematology 8/23/2021
Rituximab for eradicating inhibitors in people with acquired haemophilia A 8/23/2021
Detailed analysis of anti-emicizumab antibody decreasing drug efficacy, using plasma samples from a patient with hemophilia A 8/21/2021
A qualitative study on the experiences of haemophilia carriers before, during and after pregnancy 8/20/2021
Human coagulation factor IX: a systematic review of its characteristics 8/20/2021
The asialoglycoprotein receptor minor subunit gene (ASGR2) contributes to pharmacokinetics of factor VIII concentrates in Hemophilia A 8/19/2021
Clotting factor concentrates for preventing bleeding and bleeding-related complications in previously treated individuals with haemophilia A or B 8/18/2021
Pharmacokinetics of perioperative FVIII in adult patients with haemophilia A: An external validation and development of an alternative population pharmacokinetic model 8/18/2021
A new hemophilia carrier nomenclature to define hemophilia in women and girls: Communication from the SSC of the ISTH 8/18/2021
An update of the current pharmacotherapeutic armamentarium for hemophilia A 8/18/2021
Immune tolerance induction in severe haemophilia A: A UKHCDO inhibitor and paediatric working party consensus update 8/17/2021
Regulation and importance of factor VIII levels in hemophilia A carriers 8/16/2021
Feasibility of therapeutic plasma exchange-based combination therapy in the treatment of acquired hemophilia A: A retrospective 6 case series 8/16/2021
Cost-effectiveness Analysis of Prophylaxis Versus On-demand Treatment for Children With Hemophilia B Without Inhibitors in China 8/16/2021
Tolerogenic form of Factor VIII to Prevent Inhibitor Development in the Treatment of Hemophilia A 8/14/2021
Changes in pain profile of patients with haemophilia during 1-year follow-up 8/14/2021
Hemophilia A (Factor VIII Deficiency) 8/14/2021
Uncoupling of Bone Turnover may Compromise Skeletal Health of Young Patients With Haemophilia A 8/13/2021
Study of the Serum Immunoglobulin and Cell-Mediated Immunity in Patients with Congenital Severe Hemophilia 8/12/2021
Single centre experience on Acquired Haemophilia A patients: Diagnosis, clinical management and analysis of factors predictive of response and outcome 8/12/2021
The discovery of cryoprecipitate as a modality for hemophilia A: Augmenting the allocation of credit 8/11/2021
Complications and Management of Patients with Inherited Bleeding Disorders During Dental Extractions: a Systematic Literature Review 8/11/2021
Living with a “hemophilia-free mind” – The new ambition of hemophilia care? 8/11/2021
Emicizumab initiation and bleeding outcomes in people with hemophilia A with and without inhibitors: A single-center report 8/11/2021
Persistence of haemostatic response following gene therapy with valoctocogene roxaparvovec in severe haemophilia A 8/11/2021
Addressing unmet needs in rare bleeding disorders: Selected poster extracts of recent research in hemophilia A and von Willebrand’s disease presented at the 14th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD) (Feb 3-5, 2021; virtual congress) 8/9/2021
Evaluation of quality of life and arthropathy in the adult haemophilic patient 8/9/2021
Matching-Adjusted Indirect Comparison of Efficacy and Consumption of rVIII-SingleChain Versus Two Recombinant FVIII Products Used for Prophylactic Treatment of Adults/Adolescents with Severe Haemophilia A 8/9/2021
Evolution of congenital haemophilia care in Taiwan 8/7/2021
Update on factor (F) VIII structure and function-related hemostatic coagulation and its regulatory mechanism (s) 8/6/2021
Cost of Hemophilia A in Turkey: an economic disease burden analysis 8/6/2021
Clinical Analysis of Hospitalized Patients with Hemophilia A: Single-hemophilia Treatment Center Experience in Korea over 10 years 8/5/2021
Risk factors of inhibitor development among hemophilia patients revealed in a 10-year prospective cohort study in Japan, J-HIS2 (Japan Hemophilia Inhibitor Study 2) 8/5/2021
Correction to: A fatal unsuspected case of acquired A hemophilia. Misleading role of therapy with acetylsalicylic acid? 8/4/2021
Recognition of the unique bleeding pattern and laboratory findings in acquired haemophilia A facilitates prompt treatment of a life-threatening disorder 8/4/2021
Prostate interventions in patients with mild haemophilia: Safe and feasible 8/3/2021
European principles of care for women and girls with inherited bleeding disorders 8/3/2021
Current status of haemophilia inhibitor management in mainland China: a haemophilia treatment centres survey on treatment preferences and real-world clinical practices 8/3/2021
Haemophilia care: the only constant is change 8/3/2021
Acquired inhibitory body hemophilia : A life-threatening reason for the tendency of hematoma-genesis. 8/2/2021
Hemophilia A and C in a female: The first case report in literature 8/2/2021
A Study of ADVATE in People With Hemophilia A in India 8/2/2021
Blood’s Concentration of Lead and Arsenic Associated with Anemia in Peruvian Children 8/2/2021
Increased potency of recombinant VWF D’D3 albumin fusion proteins engineered for enhanced affinity for coagulation factor VIII 8/2/2021
Tailoring the effect of antithrombin-targeting therapy in haemophilia A using in silico thrombin generation 7/31/2021
Cullin 2-RBX1 E3 ligase and USP2 regulate antithrombin ubiquitination and stability 7/29/2021
Ankle hemophilic arthropathy: literature review 7/29/2021
Haemophilia: factoring in new therapies 7/29/2021
The Effects of Therapeutic Exercises on Kinesiophobia in Haemophilic Patients. 7/28/2021
FVIII at the crossroad of coagulation, bone and immune biology: emerging evidence of biological activities beyond hemostasis 7/27/2021
Patient preferences and priorities for haemophilia gene therapy in the US: A discrete choice experiment 7/26/2021
Gene Therapy in Hemophilia: Recent Advances 7/24/2021
Omani experience with the use of factor IX Fc fusion protein 7/24/2021
Primary membranous glomerulonephritis with negative serum PLA2R in haemophilia A successfully managed with rituximab – case report and review of the literature 7/23/2021
Clinical benefits of a Bayesian model for plasma-derived factor VIII/VWF after one year of pharmacokinetic-guided prophylaxis in severe/moderate hemophilia A patients 7/23/2021
Post-Marketing Safety Study Following Long-Term Prophylactic OptivateTreatment in Subjects With Severe Haemophilia A 7/22/2021
Gene therapy for hemophilia: Current status and laboratory consequences 7/21/2021
Optimizing factor VIII dosing in obese individuals with haemophilia A 7/21/2021
Efficacy of rFIXFc versus rIX-FP for the Treatment of Patients with Hemophilia B: Matching-Adjusted Indirect Comparison of B-LONG and PROLONG-9FP Trials 7/21/2021
Emicizumab 7/20/2021
Low-dose immune tolerance induction alone or with immunosuppressants according to prognostic risk factors in Chinese children with hemophilia A inhibitors 7/19/2021
Overcoming the challenges of treating haemophilia in resource-limited nations: a focus on medication access and adherence 7/19/2021
Genetic analysis of non-severe hemophilia A phenotype with A discrepancy between one-stage and chromogenic factor VIII activity assays 7/19/2021
Effects of short-term aerobic, resistance and combined exercises on the lipid profiles and quality of life in overweight individuals with moderate hemophilia A: A randomized controlled trial 7/19/2021
Clinical attributes and treatment characteristics are associated with work productivity and activity impairment in people with severe haemophilia A 7/17/2021
Development of Acquired Hemophilia A After Treatment of Bronchial Asthma with Benralizumab 7/16/2021
Identification and Validation of Hemophilia-Related Outcomes on Japanese Electronic Medical Record Database (Hemophilia-REAL V Study) 7/16/2021
Musculoskeletal ultrasound in hemophilia: Results and recommendations from a global survey and consensus meeting 7/16/2021
Cost-Effectiveness Analysis of rFVIIIFc Versus Contemporary rFVIII Treatments for Patients with Severe Hemophilia A Without Inhibitors in the United States 7/16/2021
An exploration of why men with severe haemophilia might not want gene therapy: The exigency study 7/15/2021
Factor VIII-Fc Activates Natural Killer Cells via Fc-Mediated Interactions With CD16 7/15/2021
The effect of emicizumab and bypassing agents in patients with hemophilia – An in vitro study 7/15/2021
Successful management of acquired hemophilia A onset during pregnancy: A case report 7/15/2021
Severe haemophilia A in a preterm girl with Turner syndrome: case report – a diagnostic and therapeutic challenge for a paediatrician (Part 2) 7/14/2021
Tailored prophylaxis in children with severe hemophilia: A four-year Iranian study 7/14/2021
Validation of PROMIS Profile-29 in adults with hemophilia in the Netherlands 7/10/2021
Optimising prophylaxis in haemophilia A: The ups and downs of treatment 7/10/2021
Final results of the PUPs B-LONG study: evaluating safety and efficacy of rFIXFc in previously untreated patients with hemophilia B 7/9/2021
Costs and management of patients with hemophilia A in France: the Hemraude study 7/8/2021
Introduction to a Review Series on gene therapy and gene editing for SCD and hemophilia 7/7/2021
Gene Therapy for Hemophilia: a review on clinical benefit, limitations and remaining issues 7/7/2021
Expert opinion paper on the treatment of hemophilia B with albutrepenonacog alfa 7/6/2021
Pharmacokinetics and complementary evaluation system-based guidance on prophylaxis of paediatric patients with haemophilia A in China with Kovaltry: protocol of the LEAP study 7/6/2021
Intra-articular Bevacizumab for Recurrent Hemarthroses at Target Joints With Chronic Hemophilic Synovitis 7/6/2021
The risk of venipuncture in newborn with severe hemophilia: Case report of a large elbow hemorrhage and literature review of compartment syndrome 7/5/2021
The Effect of Benson’s Relaxation Technique on Pain Intensity, Belief, Perception, and Acceptance in adult Hemophilia Patients: A Randomized Controlled Trial 7/5/2021
Emerging Immunogenicity and Genotoxicity Considerations of Adeno-Associated Virus Vector Gene Therapy for Hemophilia 7/2/2021
The Role of Physiotherapy in the New Treatment Landscape for Haemophilia 7/2/2021

Musculoskeletal Changes in Hemophilia Patients Subsequent to COVID-19 Lockdown 7/2/2021
Safety, Fear and Neuromuscular Responses after a Resisted Knee Extension Performed to Failure in Patients with Severe Haemophilia 7/2/2021
Hemophilic arthropathy: current knowledge and future perspectives 7/1/2021
Preferences and Health-Related Quality-of-Life Related to Disease and Treatment Features for Patients with Hemophilia A in a Canadian General Population Sample 7/1/2021
Adoption of emicizumab (Hemlibra) for hemophilia A in Europe: Data from the 2020 European Association for Haemophilia and Allied Disorders survey 6/30/2021
Efficacy, Safety and Pharmacokinetic Results of a Phase III, Open-Label, Multicenter Study with a Plasma-Derived Von Willebrand Factor (VWF)/Factor VIII (FVIII) Concentrate in Pediatric Patients <12 Years of Age with Hemophilia A (SWIFTLY-HA Study) 6/30/2021
Factor IX p.A37V mutation causes severe bleeding in a patient with phenprocoumon therapy 6/30/2021
Nonfactor Therapies: New Approaches to Prophylactic Treatment of Haemophilia 6/30/2021
Understanding the Pain Management Landscape within the US Bleeding Disorder Community: A Multi-Center Survey 6/29/2021
Structure of Blood Coagulation Factor VIII in Complex With an Anti-C2 Domain Non-Classical, Pathogenic Antibody Inhibitor 6/28/2021
Factor VIII replacement prophylaxis in patients with hemophilia A transitioning to adults: a systematic literature review 6/28/2021
Thrombin generation assay in autoimmune disease 6/28/2021
Optical or optimal conclusion: pharmacokinetic-guided dosing in haemophilia 6/26/2021
Perioperative pharmacokinetic-guided factor VIII concentrate dosing in haemophilia (OPTI-CLOT trial): an open-label, multicentre, randomised, controlled trial 6/26/2021
Pembrolizumab-induced hypothyreosis and subcutaneous bleeding 6/26/2021
The effect of emicizumab prophylaxis on long-term, self-reported physical health in persons with haemophilia A without factor VIII inhibitors in the HAVEN 3 and HAVEN 4 studies 6/25/2021
Haemophilia 6/25/2021
Impact of anticoagulation on recurrent thrombosis and bleeding after hematopoietic cell transplantation 6/24/2021
Recent Advances in the Treatment of Hemophilia: A Review 6/24/2021
Factor product utilization and health outcomes in patients with haemophilia A and B on extended half-life concentrates: A Canadian observational study of real-world outcomes 6/23/2021
Clinical characteristics and prognostic factors of acquired haemophilia A in Korea 6/22/2021
Reply to: Gene therapy to cure haemophilia: Is robust scientific inquiry the missing factor? 6/22/2021
Acquired haemophilia A: successful treatment of a patient using upfront immunosuppressive therapy and haemostatic agents 6/22/2021
Bleeding outcomes and factor utilization after switching to an extended half-life product for prophylaxis in haemophilia A in Austria 6/22/2021
Similar sports participation as the general population in Dutch persons with haemophilia; results from a nationwide study 6/19/2021
Converting factor and nonfactor usage into a single metric to facilitate benchmarking the resources consumed for haemophilia care across jurisdictions and over time 6/19/2021
Considerations on Activity Assay Discrepancies in Factor VIII and Factor IX Products 6/19/2021
Non-genotoxic conditioning facilitates hematopoietic stem cell gene therapy for hemophilia A using bioengineered factor VIII 6/18/2021
Elective surgery in patients with inherited bleeding disorders: A retrospective analysis 6/18/2021
Protein residue network analysis reveals fundamental properties of the human coagulation factor VIII 6/17/2021
Effect of CpG Depletion of Vector Genome on CD8(+) T Cell Responses in AAV Gene Therapy 6/17/2021
Indications and Waiting List Priority for Deceased Donor Liver Transplantation in HIV/HCV co-infected Hemophilic Patients in Japan through Contaminated Blood Product 6/16/2021
Patients’ and parents’ satisfaction with, and preference for, haemophilia A treatments: a cross-sectional, multicentre, observational study 6/15/2021
Diagnostic Challenges in Children With Congenital Bleeding Disorders 6/14/2021
What can we expect for adolescents and adults with haemophilia switched to low-dose prophylaxis from episodic treatment for over 3 years? A real-world snapshot in China 6/12/2021
The B-Natural study-The outcome of immune tolerance induction therapy in patients with severe haemophilia B 6/12/2021
Health- and treatment outcomes of patients with hemophilia in the Netherlands, 1972-2019 6/12/2021
Variability of treatment modalities and intensity in patients with severe haemophilia A on prophylaxis: results from the Italian national registry 6/11/2021
A survey on practice of circumcision in children with severe haemophilia in Eastern Mediterranean Region 6/11/2021
Natural anticoagulants: A missing link in mild to moderate bleeding tendencies 6/11/2021
Fusion of engineered albumin with factor IX Padua extends half-life and improves coagulant activity 6/10/2021
Educational needs of parents of hemophiliac children: An approach to comprehensive care 6/10/2021
Bleeding phenotype of patients with moderate haemophilia A and B assessed by thromboelastometry and thrombin generation 6/10/2021
Treatment-related risk factors for inhibitor development in non-severe hemophilia A after 50 cumulative exposure days: a case-control study 6/10/2021
A fatal unsuspected case of acquired A hemophilia. Misleading role of therapy with acetylsalicylic acid? 6/8/2021
Gene therapy now enters many clinical disciplines 6/8/2021
Bispecific antibodies for the treatment of haemophilia A 6/8/2021
New Developments in Diagnosis and Management of Acquired Hemophilia and Acquired von Willebrand Syndrome 6/7/2021
Pharmacokinetic, efficacy and safety evaluation of B-domain-deleted recombinant FVIII (SCT800) for prophylactic treatment in adolescent and adult patients with severe haemophilia A 6/5/2021
Emicizumab prophylaxis in infants with severe haemophilia A without inhibitors: Illustrative real-world cases to support shared decision-making 6/4/2021
Trends in the Use of Conventional and New Pharmaceuticals for Hemophilia Treatments Among Medicaid Enrollees, 2005-2020 6/2/2021
Personalised Prophylaxis in a Child with Haemophilia A and Type 1 Diabetes 6/2/2021
Development of a Novel Fully Functional Coagulation Factor VIII with Reduced Immunogenicity Utilizing an In silico Prediction and Deimmunization Approach 6/1/2021
Advances in gene therapy and their application to skin diseases: A review 5/29/2021
Real-world cost estimates of initiating emicizumab in US patients with haemophilia A 5/29/2021
Soft tissue releasing and serial casting for management of flexion contracture after primary total knee arthroplasty in a patient with hemophilia 5/29/2021
HemPHL: A Personal Health Library and mHealth Recommender to Promote Self-Management of Hemophilia 5/28/2021
A new “FIX” for hemophilia B gene therapy 5/28/2021
On-demand treatment with the iron chelator deferasirox is ineffective in preventing blood-induced joint damage in haemophilic mice 5/28/2021
Rare but not Abdicated: Status of Haemophilia in foothills of Himalaya, Uttarakhand: A cross-sectional study 5/27/2021
Pain management in people with hemophilia in childhood and young adulthood 5/27/2021
Effectiveness of ankle fusion in patients with hemophilia, advanced ankle degeneration, and unbearable pain for whom nonsurgical and surgical treatments have been ineffective 5/27/2021
First open-label, single-arm, prospective study of real-world use of FIX replacement therapy in a predominantly pediatric hemophilia B population in China 5/26/2021
BAX 855 PK-guided Dosing 5/25/2021
BAX 826 Dose-Escalation Safety Study 5/25/2021
Acquired Hemophilia 5/25/2021
Perspective – The case for zero bleeds and drug bioequivalence in the treatment of congenital hemophilia A in 2021 5/24/2021
HLA Variants and Inhibitor Development in Hemophilia A: A Retrospective Case-Controlled Study Using the ATHNdataset 5/24/2021
Progress in the Development of Anti-tissue Factor Pathway Inhibitors for Haemophilia Management 5/24/2021
Patient-relevant health outcomes for hemophilia care: Development of an international standard outcomes set 5/24/2021
Disruptive technology and hemophilia care: The multiple impacts of emicizumab 5/24/2021
Pharmacokinetic Study of ADVATE Reconstituted in 2 mL Sterile Water for Injection 5/24/2021
Early Prophylaxis Immunologic Challenge (EPIC) Study 5/24/2021
BAX 855 Continuation 5/24/2021
BAX 855 Pediatric Study 5/24/2021
Efficacy and Safety Study of a Recombinant Protein-Free Manufactured Factor VIII (rAHF-PFM) in Previously Untreated Hemophilia A Patients 5/24/2021
Phase 3 Efficacy and Safety Study of BAX 855 in Severe Hemophilia A Patients Undergoing Surgical Procedures 5/24/2021
Occurrence and management of severe bleeding episodes in patients with hereditary factor X deficiency 5/22/2021
Adherence to prophylaxis and its association with activation of self-management and treatment satisfaction 5/21/2021
The effect of age on the pressure pain threshold of asymptomatic ankles and knees in young individuals with haemophilia 5/21/2021
Patterns of joint damage in severe haemophilia A treated with prophylaxis 5/21/2021
Pharmacokinetic-guided prophylaxis improved clinical outcomes in paediatric patients with severe haemophilia A 5/21/2021
Measuring the impact of hemophilia on families: Development of the Hemophilia Family Impact Tool (H-FIT) 5/20/2021
Terminal half-life of FVIII and FIX according to age, blood group and concentrate type: data from the WAPPS database 5/20/2021
Effects of myofascial release on frequency of joint bleedings, joint status, and joint pain in patients with hemophilic elbow arthropathy: A randomized, single-blind clinical trial 5/20/2021
Treatment of high-risk bleeding with susoctocog alfa in a patient with acquired haemophilia A and a nosocomial severe acute respiratory syndrome coronavirus 2 infection 5/20/2021
BAX 326 (rFIX) Continuation Study 5/20/2021
BAX 326 Pediatric Study 5/20/2021
Pivotal Study (Pharmacokinetics, Efficacy, Safety) of BAX 326 (rFIX) in Hemophilia B Patients 5/20/2021
Study Investigating a PEGylated Recombinant Factor VIII (BAX 855) for Hemophilia A (PROLONG-ATE Study) 5/20/2021
A Study of a Long-Acting r-Factor 7a (Factor VIIa) in Adult Men With Hemophilia A or B 5/20/2021
Validation of the Spanish Version of the VERITAS-PRN Scale to Assess Adherence to on Demand Regimens in Patients with Hemophilia 5/19/2021
Effects of Progressive Resistance Training Compared With Aerobic Training in Patients With Hemophilia 5/19/2021
Efficacy and Safety Study of Prophylactic Versus On-Demand Treatment With Feiba NF in Subjects With Hemophilia A or B and a High Titer Inhibitor 5/19/2021
Prophylaxis Study of Recombinant Factor VIII Manufactured Protein-Free (rAHF-PFM) in Patients With Hemophilia A 5/19/2021
Dose-Response Study of Recombinant Factor VIII Manufactured Protein-Free (rAHF-PFM) in Patients With Hemophilia A 5/19/2021
Pharmacokinetic Comparison of Advate rAHF-PFM With Recombinate rAHF in Patients With Severe Hemophilia A 5/19/2021
Pharmacokinetic Study of ADVATE 3000 IU in Previously Treated Patients With Severe Hemophilia A 5/19/2021
BAX 326 Surgery Study in Hemophilia B Patients 5/19/2021
Phase 3/4 Study of a Recombinant Protein-Free Factor VIII (rAHF-PFM): Comparison of Continuous Infusion Versus Intermittent Bolus Infusion in Hemophilia A Subjects Undergoing Major Orthopedic Surgery 5/19/2021

A Study to Investigate the Safety, Tolerability, PK and PD of MG1113 in Healthy Subjects and Hemophilia Patients 5/19/2021
Reappearance of inhibitor in a tolerized patient with severe haemophilia A during FVIII-free emicizumab therapy 5/18/2021
RNAi targeting heparin cofactor II promotes hemostasis in hemophilia A 5/17/2021
Expert opinion on the UK standard of care for haemophilia patients with inhibitors: a modified Delphi consensus study 5/17/2021
The effectiveness of cognitive-behavioural therapy on emotional regulation and quality of life in children with Haemophilia 5/17/2021
How to Manage a Patient with Haemophilia and ACS Requiring PCI: A Battle between Bleeding and Thrombosis 5/14/2021
Gene therapy in PIDs, hemoglobin, ocular, neurodegenerative, and hemophilia B disorders 5/14/2021
Incapacitating pain from Tenofovir Induced Hypophosphatemic Osteomalacia in a Hemophilia Patient – A Case Report 5/14/2021
Performance of a clinical risk prediction model for inhibitor formation in severe haemophilia A 5/14/2021
Concomitant use of bypassing agents with emicizumab for people with haemophilia A and inhibitors undergoing surgery 5/14/2021
Study of Modified Recombinant Factor VIII (OBI-1) in Subjects With Congenital Hemophilia A 5/14/2021
Study of Modified Recombinant Factor VIII (OBI-1) in Subjects With Acquired Hemophilia A 5/13/2021
Characterisation and application of recombinant FVIII-neutralising antibodies from haemophilia A inhibitor patients 5/11/2021
Recombinant Factor VIIa BI (rFVIIa BI) Treatment of Acute Bleeding Episodes Per an On-demand Regimen 5/11/2021
Lupus anticoagulant-hypoprothrombinaemia syndrome: subdural haematoma as an unusual and initial manifestation 5/10/2021
The Possible Non-Mutational Causes of FVIII Deficiency: Non-Coding RNAs and Acquired Hemophilia A 5/10/2021
Effect of FVIII doses on joint structure and function in adolescents with severe hemophilia A: mid-term results of a prospective cohort study 5/8/2021
Identification of a modified coagulation factor X with enhanced activation properties as potential hemostatic agent 5/8/2021
Blood transfusion services amidst the COVID-19 pandemic 5/7/2021
Feasibility, safety and acceptability of select outcome measures in a physiotherapy study protocol for boys with haemophilia 5/7/2021
A tailored intervention for illness acceptance improves adherence and quality of life in adults with haemophilia using prophylaxis 5/7/2021
Study to Evaluate Safety and Tolerability of a Single Dose of PF-06741086 in Chinese Adult Participants With Severe Hemophilia 5/7/2021
Pilot Evaluation of a Motivational Interviewing Intervention Targeting Adherence Behaviors in Youth With Hemophilia 5/7/2021
Management of anticoagulation associated reproductive tract bleeding in adolescent and young adult females – Results of a multinational survey 5/7/2021
A Cross-National Survey of People Living with Hemophilia: Impact on Daily Living and Patient Education in Central Europe 5/6/2021
Coexistence of Acquired Hemophilia and Antiphospholipid Serology in Monoclonal Gammopathy Patient 5/6/2021
Viral hepatitis in haemophilia: historical perspective and current management 5/6/2021
Comparative analysis of the pivotal studies of extended half-life recombinant FVIII products for treatment of haemophilia A 5/6/2021
Tolerability of Molecular-targeted Agents for Hepatocellular Carcinoma Treatment in Haemophiliacs 5/6/2021
Preclinical Development of Plant-based Oral Immune Modulatory Therapy for Hemophilia B 5/5/2021
Sequence Length of HIV-1 Subtype B Increases over Time: Analysis of a Cohort of Patients with Hemophilia over 30 Years 5/5/2021
BAX 855 Dose-Escalation Safety Study 5/5/2021
Efficacy and Safety Study of a Recombinant and Protein-Free Factor VIII (rAHF-PFM) in Pediatric Patients in Canada With Hemophilia A – A Continuation of Baxter Study 060101 5/5/2021
First-in-Human and Proof-of-Mechanism Study of ARC19499 Administered to Hemophilia Patients 5/5/2021
The SLIM study-Shared medical appointments to change lifestyles of overweight people with haemophilia: A randomized multiple baseline (n-of-1) design 5/4/2021
Rehabilitation management of a triceps surae muscle injury in a young male with haemophilia A and high-titre inhibitors 5/4/2021
Safety and efficacy of BAY 94-9027, an extended-half-life factor VIII, during minor surgical procedures in patients with severe haemophilia A 5/3/2021
China ADVATE PTP Study 5/3/2021
Safety and Efficacy Study of a Recombinant and Protein-Free Factor VIII (rAHF-PFM) in Hemophilia A Patients Undergoing Surgery 5/3/2021
Study of Pharmacokinetics, Efficacy and Safety of a Recombinant and Protein-Free Factor VIII (rAHF-PFM) in Hemophilia A Patients – A Continuation of Clinical Study 069901 5/3/2021
T Cell-Mediated Immune Responses to AAV and AAV Vectors 4/30/2021
Association between reported medication adherence and health-related quality of life in adult patients with haemophilia 4/30/2021
Improvements in Communication and Coordination of Care in a Hemophilia Treatment Center 4/30/2021
Successful treatment of COVID-19 in a patient with severe haemophilia A on emicizumab prophylaxis in the intensive care unit 4/30/2021
Developing clinical practice guidelines for physiotherapists working with people with inherited bleeding disorders 4/30/2021
Effect of Pulsed Electromagnetic Fields on Clinical Signs and Quality of Life in Patients with Hemophilic Arthropathy of the Knee Joint: A Randomized Controlled Trial 4/29/2021
Optimizing language for effective communication of gene therapy concepts with hemophilia patients: a qualitative study 4/29/2021
A Study to Evaluate the Pharmacokinetics，Safety and Tolerability of PEG Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection 4/29/2021
Pharmacokinetics, Efficacy and Safety Study of IMMUNATE SD (Human Plasma-Derived Coagulation Factor VIII Concentrate) in Hemophilia A Patients 4/29/2021
Gene therapy may not be as expensive as people think: challenges in assessing the value of single and short-term therapies 4/28/2021
The effectiveness and value of emicizumab and valoctocogene roxaparvovec for the management of hemophilia A without inhibitors 4/28/2021
Acquired hemophilia as the initial manifestation of colorectal cancer’s recurrence 4/28/2021
Study of Pharmacokinetics, Efficacy, and Safety of a Recombinant and Protein-Free Factor VIII (rAHF-PFM) in Pediatric Patients With Hemophilia A 4/27/2021
Discrepant Diagnostic Results of Nested Polymerase Chain Reaction-based Genotyping in a Patient with Hepatitis C Virus and Human Immunodeficiency Virus Coinfection 4/26/2021
Role of Regulatory Cells in Immune Tolerance Induction in Hemophilia A 4/26/2021
The Cost-effectiveness of Gene Therapy for Severe Hemophilia B: Microsimulation Study from the United States Perspective 4/26/2021
Evolution of haemophilia integrated care in the era of gene therapy: Treatment centre’s readiness in United States and EU 4/24/2021
IMMUNINE Pre-Treatment Study 4/23/2021
Manual Therapy Effectively Decreases the Frequency of Joint Bleeding Improves Joint Health and Reduces Pain in Hemophilic Elbow Arthropathy: A Prospective Cohort Study 4/22/2021
Osteoporosis and MRI Study in Hemophilia 4/22/2021
Breakthrough Bleeding Episodes at Minimum and Improvement in Quality of Life in a Child with Severe Hemophilia A with Inhibitors Treated with Emicizumab: A Case Report from Chile 4/22/2021
Acquired hemophilia A associated with Epstein-Barr-virus-associated T/natural killer-cell lymphoproliferative disease: A case report 4/21/2021
Characteristics, complications, and sites of bleeding among infants and toddlers less than 2 years of age with VWD 4/21/2021
Management of children with hemophilia A: How emicizumab has changed the landscape 4/20/2021
Case report: successful perioperative management of patients with haemophilia A using an extended half-life factor VIII (Efmoroctocog alfa) during neurosurgical procedures 4/19/2021
Acquired haemophilia in patients with malignant disease: A case report 4/19/2021
Patient selection for hemophilia gene therapy: Real-life data from a single center 4/19/2021
Updating the Canadian Hemophilia Outcomes-Kids’ Life Assessment Tool (CHO-KLAT) in the era of extended half-life clotting factor concentrates 4/19/2021
First observation of inhibitor development against efmoroctocog alfa in France 4/19/2021
Consensus Recommendations for Intramuscular COVID-19 Vaccination in Patients with Hemophilia 4/16/2021
Spinal epidural hematoma in a child with hemophilia A with high titer inhibitors and follow-up with prophylactic emicizumab: case report and literature review 4/16/2021
Consensus of Chinese expert on the diagnosis and treatment of rare bleeding disorders (version 2021) 4/16/2021
Phase III Expansion Trial for Determining the Safety and Efficacy of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection in Adolescent and Adult Patients With Hemophilia A 4/15/2021
Optimizing the Use of Prophylaxis in Patients With Severe Haemophilia A 4/13/2021
Understanding the evolution of coverage policies for prophylaxis treatments of hemophilia A without inhibitors: a payer Delphi panel 4/13/2021
Impact of COVID-19 Pandemic on Medical Care of Patients with Inherited Bleeding Disorders 4/9/2021
A rare case of spontaneous haemothorax in patient with haemophilia A 4/8/2021
Acquired hemophilia A with reappearance of inhibitor 10 years after the completion of immunosuppressive therapy 4/8/2021
Correlation between Hemophilia Early Arthropathy Detection with Ultrasound (HEAD-US) score and Hemophilia Joint Health Score (HJHS) in patients with hemophilic arthropathy 4/7/2021
Efficacy and Safety of Shea Nut Oil in Hemophilic Arthropathy 4/6/2021
Study of Recombinant Factor IX Product, IB1001, in Subjects With Hemophilia B 4/6/2021
Confirmed long-term safety and efficacy of prophylactic treatment with BAY 94-9027 in severe haemophilia A: final results of the PROTECT VIII extension study 4/5/2021
Consensus on hemophilia in Mexico 4/5/2021
A Study of Marstacimab to Compare Prefilled Pen (PFP) Device to Prefilled Syringe (PFS) Device 4/5/2021
Post-authorization pharmacovigilance for hemophilia in Europe and the USA: Independence and transparency are keys 4/3/2021
Long-Term Follow-Up of a Portuguese Single-Centre Cohort of Persons with Haemophilia and Hepatitis C Virus Infection 4/1/2021
Making treatment decisions in hemophilia based on available safety data 4/1/2021
Activated factor X targeted stored in platelets as an effective gene therapy strategy for both hemophilia A and B 3/30/2021
The Function of extravascular coagulation factor IX in haemostasis 3/30/2021
Treatment outcomes in persons with severe haemophilia B in the Nordic region: The B-NORD study 3/30/2021
Skull hemophilia pseudotumor: A case report 3/29/2021
Pharmacokinetic variability of factor VIII concentrates in Chinese pediatric patients with moderate or severe hemophilia A 3/29/2021
Maternal and neonatal bleeding complications in relation to peripartum management in hemophilia carriers: A systematic review 3/29/2021
“They Don’t Really Take My Bleeds Seriously”: Barriers to Care for Women with Inherited Bleeding Disorders 3/29/2021
Haemophilia, state of the art and new therapeutic opportunities, a regulatory perspective 3/27/2021
Results of a randomized phase III/IV trial comparing intermittent bolus versus continuous infusion of antihaemophilic factor (recombinant) in adults with severe or moderately severe haemophilia A undergoing major orthopaedic surgery 3/27/2021
Current and Future Options of Haemophilia A Treatments 3/26/2021
Patient Preferences to Assess Value IN Gene Therapies: Protocol Development for the PAVING Study in Hemophilia 3/26/2021
Treatment of a hemophilia B mouse model with platelet-targeted expression of factor IX Padua 3/25/2021
Congenital Combined Bleeding Disorders, a Comprehensive Study of a Large Number of Iranian Patients 3/25/2021

Hemophilia 3/24/2021
Tranexamic Acid 3/24/2021
HOPE-B: Trial of AMT-061 in Severe or Moderately Severe Hemophilia B Patients 3/23/2021
A systematic review of physical activity in people with haemophilia and its relationship with bleeding phenotype and treatment regimen 3/23/2021
A comparison of MyPKFiT and WAPPS-Hemo as dosing tools for optimizing prophylaxis in patients with severe haemophilia A treated with Octocog alfa 3/23/2021
Recombinant FVIIa in elective non-orthopaedic surgery of adults with haemophilia and inhibitors: A systematic literature review 3/23/2021
Challenges of antithrombotic therapy in the management of cardiovascular disease in patients with inherited bleeding disorders: A single-centre experience 3/22/2021
Case Report: Identification of a de novo Missense Mutation in the F8 Gene, p.(Phe690Leu)/c.2070C > A, Causing Hemophilia A: A Case Report 3/22/2021
Regenerative Surgery with Dental Implant Rehabilitation in a Haemophiliac Patient 3/22/2021
Clinical, humanistic, and economic burden of severe hemophilia B in the United States: Results from the CHESS US and CHESS US+ population surveys 3/22/2021
Correction of haemostasis can be reduced to four days for CVAD implantation in severe haemophilia A patients: Data from the PedNet study group 3/22/2021
Practical considerations for nonfactor-replacement therapies in the treatment of haemophilia with inhibitors 3/20/2021
Limited sampling strategies for accurate determination of extended half-life factor VIII pharmacokinetics in severe haemophilia A patients 3/20/2021
Gene Therapy For Hemophilia B Using CB 2679d-GT: A Novel Factor IX Variant With Higher Potency Than Factor IX Padua 3/19/2021
Persons With Hemophilia of Generation Y and Their Relatives Attitudes and Expectations From Treatment 3/18/2021
Effects of Shear Stress on Production of FVIII and vWF in a Cell-Based Therapeutic for Hemophilia A 3/18/2021
Heavy menstrual bleeding in women on anticoagulant treatment for venous thromboembolism: Comparison of high- and low-dose rivaroxaban with aspirin 3/18/2021
Extended half-life factor VIII concentrates in adults with hemophilia A: Comparative pharmacokinetics of two products 3/18/2021
The Hemarthrosis-Simulating Knee Model: A Useful Tool for Individualized Education in Patients with Hemophilia (GEFACET Study) 3/17/2021
PROTECT VIII kids extension study: Long-term safety and efficacy of BAY 94-9027 (damoctocog alfa pegol) in children with severe haemophilia A 3/16/2021
Study of Recombinant Factor IX Product, IB1001, in Previously Treated Pediatric Subjects With Hemophilia B 3/15/2021
Successful Treatment of Acquired Hemophilia A with Bortezomib Plus Low Dose Rituximab in a Patient with Renal Failure and Severe Pneumonia 3/12/2021
Study on the Dose-response Relationship of Pharmacodynamic Parameters in Patients With Hemophilia With Inhibitors 3/10/2021
Risk factors for post-extraction bleeding in patients with haemophilia: a retrospective cohort study 3/9/2021
Manual therapy reduces the frequency of clinical hemarthrosis and improves range of motion and perceived disability in patients with hemophilic elbow arthropathy. A randomized, single-blind, clinical trial 3/8/2021
A fixed ‘single vial’ dose of subcutaneous desmopressin (DDAVP) produces adequate biologic responses for persons with mild haemophilia A 3/8/2021
Activated Prothrombin Complex Concentrate-Induced Atypical Hemolytic Uremic Syndrome Treated with Eculizumab 3/8/2021
Two case reports of acquired haemophilia A as complications of alemtuzumab treatment for multiple sclerosis 3/8/2021
Cardiovascular risk factors among adult patients with haemophilia 3/8/2021
Fibrinogen Replacement Therapy for Traumatic Coagulopathy: Does the Fibrinogen Source Matter? 3/6/2021
Efficacy of rFVIIIFc versus Emicizumab for the Treatment of Patients with Hemophilia A without Inhibitors: Matching-Adjusted Indirect Comparison of A-LONG and HAVEN Trials 3/5/2021
Intensive Replacement Treatment in Haemophilia Patients With Synovitis 3/5/2021
Von Willebrand disease: What does the future hold? 3/5/2021
Hemostatic Management in an Infant With Neuroblastoma and Severe Hemophilia B With Extended Half-life Recombinant Factor IX Fusion Protein 3/4/2021
Pain management in hemophilia: expert recommendations 3/4/2021
Hemostatic therapy as a management strategy for acquired hemophilia: what does the future hold? 3/3/2021
Evolutionary insights into coagulation factor IX Padua and other high-specific-activity variants 3/3/2021
B cell activating factor modulates the factor VIII immune response in hemophilia A 3/2/2021
Vaccination against COVID-19: Rationale, modalities and precautions for patients with haemophilia and other inherited bleeding disorders 3/2/2021
Recombinant factor viii fc for the treatment of haemophilia A 3/2/2021
Effects of a non-pharmacological approach for chronic pain management in patients with haemophilia: efficacy of cognitive-behavioural therapy associated with physiotherapy 3/2/2021
Health care resource utilization and costs among adult patients with hemophilia A on factor VIII prophylaxis: an administrative claims analysis 3/1/2021
Platelet-targeted hyperfunctional FIX gene therapy for hemophilia B mice even with preexisting anti-FIX immunity 3/1/2021
Tamoxifen Therapy for Recurrent Mucosal Bleeding in Hereditary Hemorrhagic Telangiectasia 3/1/2021
Restoration of FVIII Function and Phenotypic Rescue in Hemophilia A Mice by Transplantation of MSCs Derived From F8-Modified iPSCs 3/1/2021
Ascending Dose Study of Genome Editing by Zinc Finger Nuclease Therapeutic SB-FIX in Subjects With Severe Hemophilia B 3/1/2021
Study of Emicizumab Prophylaxis in Participants With Hemophilia A With or Without Inhibitors Undergoing Minor Surgical Procedures 3/1/2021
Ex Vivo Prediction of Comprehensive Coagulation Potential Using Simulated Blood Concentrations of Emicizumab in Patients with Acquired Hemophilia A 3/1/2021
Gene Therapy for Inherited Bleeding Disorders 2/27/2021
Heterogeneity in Bleeding Tendency and Arthropathy Development in Individuals with Hemophilia 2/27/2021
Virtual reality rehabilitation in paediatric patients with hemophilia. Retrospective study 2/26/2021
Predicted coagulation potential using an in vitro simulated model of emicizumab prophylaxis and immune tolerance induction therapy in hemophilia A patients with inhibitor 2/26/2021
Once-weekly prophylaxis regimen of nonacog alfa in patients with hemophilia B: an analysis of timing of bleeding event onset 2/26/2021
Development and desensitization therapy of high-response factor VIII inhibitors with severe allergic reaction in a moderate hemophilia A patient 2/25/2021
Acquired hemophilia A: clinical and biological characteristics and therapeutic management of a series of eight patients hospitalized in Lariboisiere and Saint-Louis hospitals 2/24/2021
Study of Recombinant Human Coagulation Factor VIIa for Injection (FⅦa) in Patients With Hemophilia. 2/24/2021
Cementless total hip arthroplasty in haemophilia patients through direct anterior approach 2/24/2021
Factor VIIa induces extracellular vesicles from the endothelium: A potential mechanism for its hemostatic effect 2/24/2021
Patients with haemophilia A with inhibitors in China: a national real-world analysis and follow-up 2/24/2021
Multidisciplinary Team Management of Severe Hemophilia A with Non-ST Elevation Myocardial Infarction 2/24/2021
Physical activity and bleeding outcomes among people with severe hemophilia on extended half-life or conventional recombinant factors 2/24/2021
Prothrombin Complex Concentrate 2/24/2021
Life-threatening bleeding in a patient with pemphigoid-induced acquired hemophilia A and successfully treated with rituximab and rFVIIa: A case report 2/24/2021
Haemophilia early arthropathy detection with ultrasound and haemophilia joint health score in the moderate haemophilia (MoHem) study 2/24/2021
Outcomes for studies assessing the efficacy of hemostatic therapies in persons with congenital bleeding disorders 2/24/2021
Functional and joint evaluation in a prospective cohort of patients with severe haemophilia 2/24/2021
Long-term joint outcomes of regular low-dose prophylaxis in Chinese children with severe haemophilia A 2/24/2021
Acquired haemophilia A in the postpartum and risk of relapse in subsequent pregnancies: A systematic literature review 2/24/2021
Trends in coagulation factor replacement therapy and medical costs in patients with haemophilia in Taiwan: A population-based, 15-year analysis 2/24/2021
Exploratory in vitro evaluation of thrombin generation of eptacog beta (recombinant human fviia) and emicizumab in congenital haemophilia A plasma 2/24/2021
Conservative therapy for spinal epidural hematoma in a child with hemophilia A with high-titer VIII inhibitors 2/24/2021
Immune Responses to Plasma-Derived Versus Recombinant FVIII Products 2/24/2021
Acquired Hemophilia A and urothelial carcinoma 2/24/2021
Major differences in clinical presentation, diagnosis and management of men and women with autosomal inherited bleeding disorders 2/24/2021
Challenges and concerns of patients with congenital bleeding disorders affected by coronavirus disease 2019 2/23/2021
Clot waveform analysis for perioperative hemostatic monitoring of arthroscopic synovectomy in a pediatric patient with hemophilia A and inhibitor receiving emicizumab prophylaxis 2/23/2021
Molecular determinants of the factor VIII/von Willebrand factor complex revealed by BIVV001 cryo-electron microscopy 2/23/2021
Concizumab: a novel anti-TFPI therapeutic for hemophilia 2/23/2021
Health-related quality of life and health status in adolescent and adult people with haemophilia A without factor VIII inhibitors-A non-interventional study 2/23/2021
Novel treatments for hemophilia through rebalancing of the coagulation cascade 2/23/2021
Lower physical activity and altered body composition in patients with haemophilia compared with healthy controls 2/23/2021
Simoctocog Alfa (Nuwiq) in Previously Untreated Patients with Severe Haemophilia A: Final Results of the NuProtect Study 2/23/2021
Iliopsoas Hematomas in a Patient with Progressive Encephalomyelitis with Rigidity and Myoclonus 2/23/2021
Phase 4 Safety and Efficacy Study of Antihemophilic Factor (Recombinant) in Previously Treated Chinese Patients With Severe/Moderately Severe Hemophilia A 2/23/2021
Targeting of antithrombin in hemophilia A or B with investigational siRNA therapeutic fitusiran – results of the phase 1 inhibitor cohort 2/23/2021
Using an educational intervention to assess and improve disease-specific knowledge and health literacy and numeracy in adolescents and young adults with haemophilia A and B 2/23/2021
Adult lifetime cost of hemophilia B management in the US: Payer and societal perspectives from a decision analytic model 2/23/2021
Idiopathic Acquired Hemophilia A, a Rare Cause of Bleeding: A Case Report and Literature Review 2/23/2021
A cost-effectiveness analysis of the prophylaxis versus on-demand regimens in severe hemophilia A patients under 12 years old in southern Iran 2/23/2021
Aquatic exercise in patients with haemophilia: Electromyographic and functional results from a prospective cohort study 2/23/2021
Acquired Hemophilia A in an Elderly Patient on Apixaban Therapy 2/23/2021
Acquired hemophilia in a 7-year-old girl successfully treated with recombinant FVIIA and steroids: A case report 2/23/2021
Hemophilia Gene Therapy: Approaching the First Licensed Product 2/23/2021
Recent advances in surgery and its perioperative treatment in people with hemophilia 2/23/2021
Safety evaluation of emicizumab prophylaxis in individuals with haemophilia A 2/23/2021
Ultrasound evaluation of joint damage and disease activity in adult patients with severe haemophilia A using the HEAD-US system 2/23/2021
How to implement medical and patient associations in low-income countries: A proposition from the African French Alliance for the Treatment of Haemophilia (AFATH) 2/23/2021
Bilateral renal haematuria and obstructive renal failure from acquired haemophilia A: a medical cause for a surgical problem. 2/23/2021
Safety evaluation of emicizumab prophylaxis in individuals with haemophilia A. 2/23/2021
Alphanate in Immune Tolerance Induction Therapy 2/21/2021

Hemophilia Gene Therapy: Approaching the First Licensed Product. 2/20/2021
Continuous infusion factor replacement in haemophilia B during and after cardiac surgery: the better choice? 2/20/2021
Inhibitor development in mild haemophilia after a major surgery for periampullary cancer (Whipple’s procedure) in an elderly man. 2/20/2021
Recent advances in surgery and its perioperative treatment in people with hemophilia. 2/20/2021
Safety, Efficacy and PK of BIVV001 in Pediatric Patients With Hemophilia A 2/18/2021
Idiopathic Acquired Hemophilia A, a Rare Cause of Bleeding: A Case Report and Literature Review. 2/18/2021
A cost-effectiveness analysis of the prophylaxis versus on-demand regimens in severe hemophilia A patients under 12 years old in southern Iran. 2/18/2021
Aquatic exercise in patients with haemophilia: Electromyographic and functional results from a prospective cohort study. 2/18/2021
Acquired Hemophilia A in an Elderly Patient on Apixaban Therapy. 2/18/2021
Understanding haemophilia caregiver burden: does appraisal buffer the impact of haemophilia on caregivers over time? 2/17/2021
Benign endobronchial lesion causing massive haemoptysis in a patient with haemophilia B. 2/17/2021
Using an educational intervention to assess and improve disease-specific knowledge and health literacy and numeracy in adolescents and young adults with haemophilia A and B. 2/17/2021
Adult lifetime cost of hemophilia B management in the US: Payer and societal perspectives from a decision analytic model. 2/17/2021
Iliopsoas Hematomas in a Patient with Progressive Encephalomyelitis with Rigidity and Myoclonus. 2/16/2021
Phase 4 Safety and Efficacy Study of Antihemophilic Factor (Recombinant) in Previously Treated Chinese Patients With Severe/Moderately Severe Hemophilia A. 2/16/2021
Targeting of antithrombin in hemophilia A or B with investigational siRNA therapeutic fitusiran – results of the phase 1 inhibitor cohort. 2/16/2021
Effect of Exercise in Pediatric Hemophilia 2/15/2021
Simoctocog Alfa (Nuwiq) in Previously Untreated Patients with Severe Haemophilia A: Final Results of the NuProtect Study. 2/14/2021
Hematological Diseases and Osteoporosis. 2/13/2021
COVID-19 and telemedicine in haemophilia in a patient with severe haemophilia A and orthopaedic surgery. 2/13/2021
Health-related quality of life and health status in adolescent and adult people with haemophilia A without factor VIII inhibitors-A non-interventional study. 2/13/2021
Novel treatments for hemophilia through rebalancing of the coagulation cascade. 2/13/2021
Lower physical activity and altered body composition in patients with haemophilia compared with healthy controls. 2/13/2021
Molecular determinants of the factor VIII/von Willebrand factor complex revealed by BIVV001 cryo-electron microscopy. 2/12/2021
Concizumab: a novel anti-TFPI therapeutic for hemophilia. 2/12/2021
ASH ISTH NHF WFH 2021 guidelines on the management of von Willebrand disease. 2/12/2021
Clot waveform analysis for perioperative hemostatic monitoring of arthroscopic synovectomy in a pediatric patient with hemophilia A and inhibitor receiving emicizumab prophylaxis. 2/11/2021
A Safety Study of STSP-0601 in Adult Patients With Hemophilia A or B With Inhibitor 2/10/2021
Challenges and concerns of patients with congenital bleeding disorders affected by coronavirus disease 2019. 2/10/2021
BAY 81-8973 demonstrated efficacy, safety and joint status improvement in patients with severe haemophilia A in the LEOPOLD I extension for ≤2 years. 2/9/2021
Conservative therapy for spinal epidural hematoma in a child with hemophilia A with high-titer VIII inhibitors. 2/9/2021
Immune Responses to Plasma-Derived Versus Recombinant FVIII Products. 2/9/2021
Acquired Hemophilia A and urothelial carcinoma. 2/9/2021
Major differences in clinical presentation, diagnosis and management of men and women with autosomal inherited bleeding disorders. 2/9/2021
Effect of variations in the conserved residues E371 and S359 on the structural dynamics of protein Z dependent protease inhibitor (ZPI): a molecular dynamic simulation study. 2/9/2021
Emicizumab improves thrombus formation of type 2A von willebrand disease under high shear condition. 2/9/2021
Haemophilia early arthropathy detection with ultrasound and haemophilia joint health score in the moderate haemophilia (MoHem) study. 2/9/2021
Outcomes for studies assessing the efficacy of hemostatic therapies in persons with congenital bleeding disorders. 2/9/2021
Efficacy and safety of a recombinant Von Willebrand Factor treatment in patients with inherited Von Willebrand Disease requiring surgical procedures. 2/9/2021
Functional and joint evaluation in a prospective cohort of patients with severe haemophilia. 2/9/2021
Long-term joint outcomes of regular low-dose prophylaxis in Chinese children with severe haemophilia A. 2/9/2021
Acquired haemophilia A in the postpartum and risk of relapse in subsequent pregnancies: A systematic literature review. 2/9/2021
Trends in coagulation factor replacement therapy and medical costs in patients with haemophilia in Taiwan: A population-based, 15-year analysis. 2/9/2021
Exploratory in vitro evaluation of thrombin generation of eptacog beta (recombinant human fviia) and emicizumab in congenital haemophilia A plasma. 2/9/2021
An Open-label Extension Study of an Investigational Drug, Fitusiran, in Patients With Moderate or Severe Hemophilia A or B 2/8/2021
Life-threatening bleeding in a patient with pemphigoid-induced acquired hemophilia A and successfully treated with rituximab and rFVIIa: A case report. 2/7/2021
Multidisciplinary Team Management of Severe Hemophilia A with Non-ST Elevation Myocardial Infarction. 2/5/2021
Physical activity and bleeding outcomes among people with severe hemophilia on extended half-life or conventional recombinant factors. 2/5/2021
Emicizumab in Acquired Hemophilia A 2/4/2021
Ankle arthrodesis for end-stage haemophilic ankle arthropathy using a Ilizarov method. 2/4/2021
Factor VIIa induces extracellular vesicles from the endothelium: A potential mechanism for its hemostatic effect. 2/4/2021
Patients with haemophilia A with inhibitors in China: a national real-world analysis and follow-up. 2/4/2021
Principles of Care for Acquired Hemophilia. 2/3/2021
Characterization of protein unable to bind von Willebrand factor in recombinant factor VIII products. 2/3/2021
Structure of Blood Coagulation Factor VIII in Complex with an Anti-C1 Domain Pathogenic Antibody Inhibitor. 2/3/2021
Characterization of a plasma-derived double-viral-inactivated factor VIII concentrate (antihaemophilic factor [human]): Focus on TTP treatment. 2/3/2021
Cementless total hip arthroplasty in haemophilia patients through direct anterior approach. 2/3/2021
BAX 802 in CHA With Inhibitors 2/2/2021
Pain Prevalence, Characteristics, and Impact Among People with Hemophilia: Findings from the First Portuguese Survey and Implications for Pain Management. 2/2/2021
Major surgery management in patients with haemophilia A and inhibitors on emicizumab prophylaxis without global coagulation monitoring. 2/2/2021
Immunoadsorption for the Treatment of Acquired Hemophilia: New Observational Data, Systematic Review, and Meta-Analysis. 2/2/2021
Approximation of emicizumab plasma levels in emergency situations. A practical approach. 2/2/2021
Identified unmet needs and proposed solutions in mild-to-moderate haemophilia: A summary of opinions from a roundtable of haemophilia experts. 2/2/2021
Impact of haemophilia on patients with mild-to-moderate disease: Results from the P-FiQ and B-HERO-S studies. 2/2/2021
Current challenges for men and women with mild-to-moderate haemophilia. 2/2/2021
ABO Blood Group and Inhibitor Risk in Severe Hemophilia A Patients: A Study from the Italian Association of Hemophilia Centers. 2/2/2021
Hemophilia care in Africa: status and challenges. 1/31/2021
Heavy menstrual bleeding in women with inherited bleeding disorders. 1/30/2021
Investigator clinical trials: How can we ask the question? 1/30/2021
The Impact of HEAD-US Scoring System for Observing the Protective Effect of Prophylaxis in Hemophilia Patients: A Prospective, Multicenter, Observational Study. 1/30/2021
Haemophilia care and outcome in a major haemophilia treatment centre in Malaysia. 1/30/2021
Demographics and outcome of patients with congenital haemophilia in Sarawak, Malaysia. 1/30/2021
Long-term outcomes with emicizumab prophylaxis for hemophilia A with/without FVIII inhibitors from the HAVEN 1-4 studies. 1/30/2021
Activated Protein C has a Regulatory Role in Factor VIII Function. 1/30/2021
A practical, one-clinic visit protocol for pharmacokinetic profile generation with the ADVATE® myPKFiT® dosing tool in severe hemophilia A subjects. 1/29/2021
Development and testing of the Satisfaction Questionnaire with Intravenous or Subcutaneous Hemophilia Injection and results from the Phase 3 HAVEN 3 study of emicizumab prophylaxis in persons with haemophilia A without FVIII inhibitors. 1/29/2021
Gene Therapy for Chinese Hemophilia A 1/28/2021
Health Related Quality of Life of Youth and Young Adults With Haemophilia A 1/28/2021
Long-Term Outcomes of Previously Treated Adult and Adolescent Patients with Severe Hemophilia A Receiving Prophylaxis with Extended Half-Life FVIII Treatments: An Economic Analysis from a United Kingdom Perspective. 1/28/2021
Von Willebrand disease type 2N: an update. 1/27/2021
Provider Attitudes and Practices Regarding IUS Insertion in Adolescents With and Without Bleeding Disorders for Management of Heavy Menstrual Bleeding. 1/27/2021
Management of inhibitors in persons with non-severe hemophilia A in the United States. 1/26/2021
[Perioperative application of recombinant human coagulation factor Ⅶa combined with prothrombin complex in two hemophilia A patients with high titer inhibitor]. 1/26/2021
Static postural balance evaluation and an investigation of the relationship with joint health in children with severe haemophilia: a controlled cross-sectional study. 1/26/2021
[Ascending Colon Cancer with Hemophilia A Treated with Laparoscopic Right Hemicolectomy under Control of a Blood Coagulant Factor-A Case Report]. 1/22/2021
Safety and Pharmacokinetics of Subcutaneous Injection of OCTA101 in Adult Patients With Severe Hemophilia A 1/22/2021
Perioperative Bypassing Agent Therapy for Pulmonary Pleomorphic Carcinoma with Acquired Hemophilia. 1/22/2021
Assessing bleeding risk in 18 children with Osteogenesis imperfecta. 1/22/2021
Unforeseen encounter of acquired hemophilia A in a preoperative case of periampullary carcinoma: A case report. 1/22/2021
[Hepatectomy for Intrahepatic Combined Hepatocellular Carcinoma Recurrence in a Hemophilia a Patient with Human Immunodeficiency Virus and Hepatitis C Virus-A Case Report]. 1/21/2021
Acute airway compromise and coagulopathy: a rare presentation of acquired haemophilia A. 1/20/2021
Onset of acquired haemophilia A after omalizumab treatment in severe bullous pemphigoid – a report on two cases successfully treated with mycophenolate mofetil. 1/20/2021
Core data set on safety, efficacy, and durability of hemophilia gene therapy for a global registry: Communication from the SSC of the ISTH. 1/20/2021
Budget impact analysis of Jivi® (damoctocog alfa pegol, BAY 94-9027) in severe Hemophilia A in Japan. 1/20/2021
The changing treatment landscape in haemophilia: from standard half-life clotting factor concentrates to gene editing. 1/20/2021
Study to Investigate Immunogenicity, Efficacy and Safety of Treatment With Human-cl rhFVIII 1/19/2021
A Trial Evaluating the Efficacy and Safety of Prophylactic Administration of Concizumab in Haemophilia A and B Patients With Inhibitors 1/19/2021
Human Cell Line-derived Recombinant Factor VIII (Human-cl-rhFVIII) in Previously Untreated Patients 1/19/2021
Assess the Efficacy and Safety of Personalized Prophylaxis Human-cl rhFVIII in Patients With Severe Haemophilia A 1/19/2021
Clinical Study to Investigate the PK, Efficacy, and Safety of Wilate in Patients With Severe Hemophilia A 1/19/2021

Pharmacokinetics, Efficacy, Safety, and Immunogenicity of Wilate in Previously Treated Paediatric Patients With Severe Haemophilia A 1/19/2021
Real-world evidence on Kovaltry (81-8973) in children with moderate or severe hemophilia A in Europe: a nested cohort analysis. 1/17/2021
Conservative management of duodenal haematoma in a patient with severe haemophilia: A case report and literature review. 1/16/2021
North-eastern Brazilian recommendations for the nurse professional role on the pharmacokinetic-assisted prophylaxis individualization for haemophilia A. 1/16/2021
Long-term impact of haemarthrosis on arthropathy and activities of daily living in Japanese persons with haemophilia. 1/16/2021
Hepatitis C and history of FVIII inhibitor development in a long-term cohort of Brazilian patients with haemophilia A. 1/16/2021
A boy with joint pain associated with emicizumab treatment: The importance of plasma level measurement. 1/16/2021
Continuous infusion of recombinant porcine factor VIII for neurosurgical management of intracranial haemorrhage in a patient with severe haemophilia A with factor VIII inhibitor. 1/16/2021
Target-Mediated Drug Disposition (TMDD) Modeling of an Anti-TFPI Antibody (MG1113) in Cynomolgus Monkeys to Predict Human Pharmacokinetics and Pharmacodynamics. 1/16/2021
QALY league table of Iran: a practical method for better resource allocation. 1/15/2021
Surgical treatment of hemophilic pseudotumor with severe bone destruction: a case report. 1/15/2021
PHILEOS (haemoPHILia and ostEoporOSis) Study: protocol of a multicentre prospective case-control study. 1/15/2021
Translating the success of prophylaxis in haemophilia to von Willebrand disease. 1/15/2021
Acquired haemophilia A treated with recombinant porcine factor VIII: a single centre UK experience. 1/12/2021
Gene Therapy Trial for Platelet Derived Factor VIII Production in Hemophilia A 1/12/2021
Acquired hemophilia A and delta storage pool deficiency in a patient with indolent non-Hodgkin lymphoma. 1/12/2021
Assessment of Lebanese healthcare professionals’ awareness on acquired haemophilia: a cross-sectional study. 1/12/2021
Primary thromboprophylaxis in a patient with type 3 von Willebrand disease and severe COVID-19 infection. 1/12/2021
Long-term Safety and Efficacy Study and Dose-Escalation Substudy of PF 06838435 in Individuals With Hemophilia B 1/11/2021
The Effects of Exercise Training in Children With Hemophilia 1/11/2021
The effects of manual therapy on musculoskeletal system, functional level, joint health and kinesiophobia in young adults with severe haemophilia: A randomized pilot study. 1/11/2021
Magnetic Resonance Imaging of Hemophilic Joints: Correlations with the Bleeding Phenotype and Physical Examination. 1/9/2021
Study to Evaluate the Safety, Pharmacokinetics and Efficacy of Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) in Previously Treated Subjects With Severe Hemophilia A 1/8/2021
Content analysis of identity challenges in patients with haemophilia: A qualitative study. 1/7/2021
Procoagulant platelets: Laboratory detection and clinical significance. 1/6/2021
Epidemiological Challenges in Rare Bleeding Disorders: FVIII Inhibitor Incidence in Haemophilia A Patients-A Known Issue of Unknown Origin. 1/6/2021
Kid Cards: Teaching Kids About Medicines 1/5/2021
Evaluation of bleeding symptoms and laboratory parameters related to bleeding in sisters of patients with hemophilia A and B. 1/5/2021
Prevalence of and risk factors for urolithiasis in Croatian patients with hemophilia. 1/4/2021
Knee radiosynovectomy with 153Sm-hydroxyapatite compared to 90Y-hydroxyapatite: initial results of a prospective trial. 1/4/2021
Procoagulant imbalance in Klinefelter syndrome assessed by thrombin generation assay and whole blood thromboelastometry. 1/1/2021
Recombinant FVIIIFc Versus BAY 94-9027 for Treatment of Patients with Haemophilia A: Comparative Efficacy Using a Matching Adjusted Indirect Comparison. 12/31/2020
POCUS: Hemostatic Potential and Joint Health in Patients With Severe Hemophilia A on Novel Replacement Therapies 12/30/2020
Safety and Tolerability Study of OP-724 in Liver Cirrhosis Patients by HIV/HCV With Hemophilia. 12/29/2020
The role of telemedicine in the delivery of health care in the COVID-19 pandemic. 12/29/2020
Clinical trials and Haemophilia during the COVID-19 pandemic: Madrid’s experience. 12/29/2020
Intra-articular injections in people with haemophilia in the COVID-19 era. 12/29/2020
COVID-19 coagulopathy in pregnancy: Critical review, preliminary recommendations, and ISTH registry-Communication from the ISTH SSC for Women’s Health. 12/29/2020
Incidence of inhibitor development in PUPs with severe Haemophilia A in the CEE region between 2005 and 2015. 12/29/2020
Mutation detection and inhibitor risk in Iranian patients with Hemophilia A: Six novel mutations. 12/29/2020
The Need for Comprehensive Care for Persons with Chronic Immune Thrombocytopenic Purpura. 12/29/2020
Women and girls with haemophilia and bleeding tendencies: Outcomes related to menstruation, pregnancy, surgery and other bleeding episodes from a retrospective chart review. 12/29/2020
Best quality indicator of vitamin K antagonist therapy to predict mortality and bleeding in haemodialysis patients with atrial fibrillation. 12/29/2020
Characterization of the neutralizing anti-emicizumab antibody in a patient with haemophilia A and inhibitor. 12/29/2020
Safety, Tolerability, and Efficacy Study of Valoctocogene Roxaparvovec in Hemophilia A With Active or Prior Inhibitors 12/28/2020
Rofecoxib Efficacy and Safety Evaluation Trial in Hemophilic Arthropathy 12/24/2020
Recombinant porcine FVIII for bleed treatment in acquired hemophilia A: findings from a single-center, 18-patient cohort. 12/23/2020
EMICIZUMAB THERAPY IN A HAEMOPHILIA PATIENT WITH PREVIOUS PULMONARY EMBOLISM. 12/23/2020
AIDS in the Heartland- Hemophilia was the Harbinger of Things to Come. 12/23/2020
Epidemiological data and treatment strategies in children with severe haemophilia in Italy. 12/22/2020
Enhanced Half-Life Recombinant Factor VIII Concentrates for Hemophilia A: Insights from Pivotal and Extension Studies. 12/22/2020
BT200 in Hereditary Bleeding Disorders 12/21/2020
Study to Compare How the Body Distributes and Excretes the Drugs Jivi (BAY 94-9027) and Adynovi in Patients With Severe Hemophilia A (Bleeding Disorder Resulting From a Lack of Blood Clotting Factor VIII) 12/21/2020
Long-term follow-up of hemophilia gene therapy in dogs. 12/20/2020
The potential role of emicizumab prophylaxis in severe von Willebrand disease. 12/20/2020
Pharmacokinetics of rFVIIIFc at Two Vial Strengths 12/19/2020
Pharmacokinetics and Safety of rFVIIIFc Manufactured at 15,000 L (15K) Scale 12/19/2020
Study of Recombinant Factor IX Fc Fusion Protein (rFIXFc) in Participants With Hemophilia B 12/19/2020
Study of Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) in Subjects With Severe Hemophilia A 12/19/2020
A Phase 1 Study of an Investigational Drug, ALN-AT3SC, in Healthy Volunteers and Hemophilia A or B Patients 12/19/2020
Study of Recombinant Coagulation Factor IX Fc Fusion Protein, BIIB029, in Previously Treated Pediatric Participants With Hemophilia B 12/19/2020
Long-Term Safety and Efficacy of rFIXFc in the Prevention and Treatment of Bleeding Episodes in Previously Treated Participants With Hemophilia B 12/19/2020
Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Recombinant Coagulation Factor VIII Fc Fusion Protein (rFVIIIFc) in Previously Treated Pediatric Subjects With Hemophilia A 12/19/2020
Long-Term Safety and Efficacy of rFVIIIFc in the Prevention and Treatment of Bleeding Episodes in Previously Treated Participants With Hemophilia A 12/19/2020
A Safety, Tolerability, and Pharmacokinetics Study of a Single Intravenous Injection of Recombinant Coagulation Factor VIII Fc – Von Willebrand Factor – XTEN Fusion Protein (rFVIIIFc-VWF-XTEN) (BIVV001) in Previously Treated Adults With Severe Hemophilia A (EXTEN-A) 12/19/2020
Phase I/IIa Study of FIXFc in Hemophilia B Patients 12/19/2020
ASC-618 Gene Therapy in Hemophilia A Patients 12/19/2020
Inherited bleeding disorders in oral procedures. Assessment of prophylactic and therapeutic protocols: a scoping review. 12/19/2020
Management of bleeding events and invasive procedures in patients with haemophilia A without inhibitors treated with emicizumab. 12/19/2020
Convenience Comparison Study of Reconstitution Devices for the Blood Coagulation Factor VIII Products Rurioctocog Alfa Pegol and Antihemophilic Factor (Recombinant). 12/18/2020
Application of a hemophilia mortality framework to the Emicizumab Global Safety Database. 12/18/2020
Establishment of a framework for assessing mortality in persons with congenital hemophilia A and its application to an adverse event reporting database. 12/18/2020
Mortality in congenital hemophilia A – a systematic literature review. 12/18/2020
Rescue Immunotolerance Study in Induction of Immune Tolerance (ITI)-Experienced Patients (RES.I.S.T. Experienced) 12/17/2020
Study of First TIME Immunotolerance Induction in Severe Hemophilia A Patients With Inhibitor at High Risk of Failure: Comparison With FVIII Concentrates With or Without Von Willebrand Factor – RES.I.S.T. Naive 12/17/2020
Efficacy and safety of fibrinogen concentrate for on-demand treatment of bleeding and surgical prophylaxis in paediatric patients with congenital fibrinogen deficiency. 12/17/2020
Body Mass Index Best Predicts Recovery of Recombinant Factor VIII in Underweight to Obese Patients with Severe Haemophilia A. 12/15/2020
Emicizumab improves the stability and structure of fibrin clot derived from factor VIII-deficient plasma, similar to the addition of factor VIII. 12/15/2020
Do patients with von Willebrand disease exhibit higher blood loss and revision rates in hip and knee arthroplasty? A case-control study. 12/15/2020
Effects of performing dual tasks on postural sway and postural control complexity in people with haemophilic arthropathy. 12/15/2020
Why stay? Resilience in haemophilia physicians in the 1980s. 12/15/2020
The Australian experience with switching to extended half-life factor VIII and IX concentrates: On behalf of the Australian Haemophilia Centre Directors’ Organisation. 12/15/2020
Development and evaluation of the population pharmacokinetic models for FVIII and FIX concentrates of the WAPPS-Hemo project. 12/15/2020
A reprieve from hemophilia A, but for how long? 12/15/2020
Morphological characteristics and clinical significance of the distal femur in patients with hemophilia-related knee arthritis. 12/15/2020
Current Clinical Applications of in vivo Gene Therapy with AAVs. 12/15/2020
Early Phase Clinical Immunogenicity of Valoctocogene roxaparvovec, an AAV5-Mediated Gene Therapy for Hemophilia A. 12/15/2020
Minimal Essential Human Factor VIII Alterations Enhance Secretion and Gene Therapy Efficiency. 12/15/2020
Effect of anticoagulants on fibrin clot structure: A comparison between vitamin K antagonists and factor Xa inhibitors. 12/15/2020
MG1113, a specific anti-tissue factor pathway inhibitor antibody, rebalances the coagulation system and promotes hemostasis in hemophilia. 12/15/2020
Turoctocog alfa is safe for the treatment of Indian patients with hemophilia A: Guardian 10 trial results. 12/15/2020
Managing women-specific bleeding in inherited bleeding disorders: A multidisciplinary approach. 12/15/2020
Genetic causes of haemophilia in women and girls. 12/15/2020
Persistent inhibitor in acquired haemophilia A: A case for emicizumab? 12/15/2020
Safety and effectiveness of Rixubis in patients with hemophilia B: A real-world, prospective, postmarketing surveillance study in South Korea. 12/12/2020
Should Emicizumab Be Used in Patients with Acquired Hemophilia A? 12/12/2020
Multicenter retrospective study of transcatheter arterial embolisation for life-threatening haemorrhage in patients with uncorrected bleeding diathesis. 12/11/2020
A feasibility study on two tailored interventions to improve adherence in adults with haemophilia. 12/10/2020
Decreased Bleeding Rates in Patients with Hemophilia A Switching from Standard-half-life FVIII to BAY 94-9207 Prophylaxis. 12/10/2020
Pathological mechanism of joint destruction in haemophilic arthropathy. 12/9/2020

A Study of Fitusiran (ALN-AT3SC) in Severe Hemophilia A and B Patients With Inhibitors 12/7/2020
Safety and efficacy of nonacog alfa for the treatment of haemophilia B in children younger than 6 years of age in a routine clinical care setting: the EUREKIX registry study. 12/6/2020
Natural history study of factor IX deficiency with focus on treatment and complications (B-Natural). 12/6/2020
Assessing the current knowledge, attitude and behaviour of adolescents and young adults living with haemophilia. 12/6/2020
Safety and Efficacy of Moroctocog Alfa (AF-CC) in Chinese Patients with Hemophilia A: Results of Two Open-Label Studies. 12/4/2020
Factors Associated with Compliance with the Treatment Protocol and Mortality in Adults with Hemophilia. 12/3/2020
Pain assessment and management in Italian Haemophilia Centres. 12/3/2020
A Trial Investigating Safety and Efficacy of Treatment With BAY94-9027 in Severe Hemophilia A 12/2/2020
A Long-Term Follow-Up Study of Haemophilia B Patients Who Have Undergone Gene Therapy 12/1/2020
Spectrum of F8 Genotype and Genetic Impact on Inhibitor Development in Patients with Hemophilia A from Multicenter Cohort Studies (J-HIS) in Japan. 12/1/2020
Safety and Efficacy of Turoctocog Alfa in Prevention and Treatment of Bleeds in Previously Untreated Children With Haemophilia A 11/30/2020
Multiple Escalating Dose Study of BAY1093884 in Adults With Hemophilia A or B With or Without Inhibitors 11/30/2020
SEVENFACT® for Bleeding Events in Hemophilia With Inhibitors 11/30/2020
Taking on a pandemic’s challenge: Emergent solutions from a single Hemophlia treatment center in North India. 11/30/2020
Activated factor VIII-mimicking effect by emicizumab on thrombus formation in type 2N von Willebrand disease under high shear flow conditions. 11/29/2020
Gastrointestinal bleeding in a newborn infant with congenital factor X deficiency and COVID-19-A common clinical feature between a rare disorder and a new, common infection. 11/28/2020
Feasibility and outcomes of low-dose and low-frequency prophylaxis with recombinant extended half-life products (Fc-rFVIII and Fc-rFIX) in Ivorian children with hemophilia: Two-year experience in the setting of World Federation of Haemophilia humanitarian aid programme. 11/28/2020
Reimbursing the value of gene therapy care in an era of uncertainty. 11/28/2020
Addressing patient education priorities in the era of gene therapy for haemophilia: Towards evidence-informed shared decision-making. 11/28/2020
An overview of patients with haemophilia A in China: Epidemiology, disease severity and treatment strategies. 11/28/2020
Safety and efficacy of percutaneous radiofrequency ablation for hepatocellular carcinoma patients with haemophilia. 11/28/2020
Comparison of bypassing agents in patients on emicizumab using global hemostasis assays. 11/28/2020
Management of people with haemophilia A undergoing surgery while receiving emicizumab prophylaxis: Real-world experience from a large comprehensive treatment centre in the US. 11/28/2020
The role of nursing in gene therapy for haemophilia. 11/27/2020
Long-term Safety and Efficacy of BIVV001 in Previously Treated Patients With Hemophilia A 11/25/2020
[Advances in gene therapy for β-thalassemia and hemophilia based on the CRISPR/Cas9 technology]. 11/25/2020
The prospective Hemophilia Inhibitor PUP Study reveals distinct antibody signatures prior to FVIII inhibitor development. 11/25/2020
Dosing of factor VIII concentrate by ideal body weight is more accurate in overweight and obese hemophilia A patients. 11/25/2020
Taking Stock of Hemophilia, Immune Thrombocytopenia, and Bone Marrow Failure. 11/24/2020
Evaluation of Safety and Efficacy, Including Pharmacokinetics, of NNC 0129-0000-1003 When Administered for Treatment and Prophylaxis of Bleeding in Subjects With Haemophilia A 11/23/2020
Joint hemorrhage accelerates cartilage degeneration in a rat immobilized knee model. 11/21/2020
Assessing patient and caregiver preferences for treatment of haemophilia A: A discrete choice experiment. 11/21/2020
Characterisation of healthcare utilisation and cost of haemophilia care in real-life: A 4-year follow-up study in Finland. 11/21/2020
Parental perspectives on gene therapy for children with haemophilia: The Exigency study. 11/21/2020
Real-world evidence on health resource use among patients with haemophilia and inhibitor exhibiting severe bleeding episodes. 11/21/2020
Evaluation of anti-factor VIII antibody levels in patients with haemophilia A receiving immune tolerance induction therapy or bypassing agents. 11/21/2020
Management of COVID-19-associated coagulopathy in persons with haemophilia. 11/21/2020
Enhancing therapeutic efficacy of in vivo platelet-targeted gene therapy in hemophilia A mice. 11/21/2020
Mortality, life expectancy and causes of death of persons with hemophilia in the Netherlands 2001-2018. 11/21/2020
Comparative analysis of oral health and treatment necessities in hemophilia individuals of Davangere population – A case control study. 11/20/2020
What COVID-19 can mean for people with hemophilia beyond the infection risk. 11/20/2020
Prevalence of AAV3 capsid binding and neutralizing antibodies in healthy and individuals with hemophilia B from India. 11/20/2020
Real-world data of immune tolerance induction using recombinant factor VIII Fc fusion protein in patients with severe haemophilia A with inhibitors at high risk for immune tolerance induction failure: A follow-up retrospective analysis. 11/20/2020
Cost-effectiveness of emicizumab vs bypassing agents in the prevention of bleeding episodes in haemophilia A patients with anti-FVIII inhibitors in France. 11/20/2020
Heavy menstrual bleeding in women on oral anticoagulants. 11/20/2020
A long-term study of AAV gene therapy in dogs with hemophilia A identifies clonal expansions of transduced liver cells. 11/18/2020
Pharmacokinetics in routine haemophilia clinical practice: rationale and modalities-a practical review. 11/17/2020
Stability of Turoctocog Alfa, a Recombinant Factor VIII Product, during Continuous Infusion In Vitro. 11/17/2020
Discussing investigational AAV gene therapy with hemophilia patients: A guide. 11/16/2020
Fibrin clot properties to assess the bleeding phenotype in unrelated patients with hypodysfibrinogenemia due to novel fibrinogen mutations. 11/16/2020
Molecular Profiling of Liver Sinusoidal Endothelial Cells in Comparison to Hepatocytes: Reflection on Which Cell Type Should Be the Target for Gene Therapy. 11/16/2020
Characterisation of a novel thrombomodulin c.1487delC,p.(Pro496Argfs*10) variant and evaluation of therapeutic strategies to manage the rare bleeding phenotype. 11/16/2020
Haemophilia, the journey in search of a cure. 1960-2020. 11/16/2020
Gene Therapy Study in Severe Hemophilia A Patients With Antibodies Against AAV5 11/16/2020
The Safety and Tolerability of SerpinPC in Healthy Men and in Men With Severe Blood Disorders (Haemophilia A and B) 11/16/2020
Open-Label Single Ascending Dose of Adeno-associated Virus Serotype 8 Factor IX Gene Therapy in Adults With Hemophilia B 11/16/2020
The Effects of Exercises on Gait in Hemophilic Individuals 11/13/2020
Diagnostic and Treatment Challenges for Acquired Hemophilia A in Pediatrics: Report of 2 Cases. 11/13/2020
Liver transplantation as potential curative method in severe hemophilia A: case report and literature review. 11/11/2020
Acquired hemophilia A in a woman with systemic lupus erythematosus: A case report and review of literature. 11/11/2020
Patient perspectives regarding gene therapy in haemophilia: Interviews from the PAVING study. 11/10/2020
[Diagnosis and management of hemophilia]. 11/10/2020
Detection and evaluation of haemophilic arthropathy: Which tools may be considered more reliable. 11/10/2020
Dose-escalation Study to Investigate the Safety, PK, and PD of ISU304/CB2679d in Hemophilia B Patients 11/10/2020
Preventing Inhibitor Recurrence Indefinitely 11/9/2020
Rurioctocog alfa pegol PK-guided prophylaxis in hemophilia A: Results from the phase 3 PROPEL study. 11/6/2020
First Report of Prevalence of Blood-Borne Viruses (HBV, HCV, HIV, HTLV-1 and Parvovirus B19) Among Hemophilia Patients in Afghanistan. 11/5/2020
Challenges facing community-dwelling adults with hemophilia: Implications for community-based adult education and nursing. 11/5/2020
Blood coagulation factor VIII D1241E polymorphism leads to a weak malectin interaction and reduction of factor VIII posttranslational modification and secretion. 11/5/2020
The bleeding score: Useful in predicting spontaneous bleeding events in adults with bleeding of unknown cause? 11/4/2020
EHL-FIX in haemophilia B carriers with FIX deficiency. 11/4/2020
Antithrombotic therapy management in patients with inherited bleeding disorders and coronary artery disease: A single-centre experience. 11/4/2020
Assessment of primary haemostasis with a new recombinant von Willebrand factor in patients with von Willebrand disease. 11/4/2020
Ligneous gingivitis: Hard to diagnose and treat. 11/4/2020
Eradication of factor IX neutralizing and anaphylactic inhibitors in a patient with severe haemophilia B using cyclophosphamide immune suppression and factor IX desensitization. 11/4/2020
Treatment of pelvic haemophilic pseudotumour: A retrospective study. 11/4/2020
Monitoring standard and extended half-life products in hemophilia: Assay discrepancies for factor VIII and IX in pre- and postinfusion samples. 11/3/2020
A Gene Transfer Study for Hemophilia A 11/3/2020
Diagnostic work up of patients with increased bleeding tendency. 11/3/2020
A single centre retrospective study of low dose prophylaxis with extended half-life factor IX for severe haemophilia B. 11/3/2020
Multicentre pharmacokinetic evaluation of rFVIII-Fc (efmoroctocog alfa) in a real life and comparison with non-extended half-life FVIII concentrates. 11/3/2020
Dose-finding Study of SPK-8016 Gene Therapy in Patients With Hemophilia A to Support Evaluation in Individuals With FVIII Inhibitors 11/2/2020
Confronting COVID-19: Issues in Hemophilia and Congenital Bleeding Disorders. 10/31/2020
Acquired hemophilia A and plasma cell neoplasms: a case report and review of the literature. 10/31/2020
Emicizumab-Induced Seronegative Full-House Lupus Nephritis in a Child. 10/31/2020
Current practices in haemophilic patients undergoing orthopedic surgery – a systematic review. 10/31/2020
The Effectiveness of Recombinant Coagulation Factor IX With Recombinant Albumin (rIX-FP) in Severe Hemophilia B Patients 10/30/2020
The German Hemophilia Registry: Growing with Its Tasks. 10/30/2020
Efficacy of prehospital administration of fibrinogen concentrate in trauma patients bleeding or presumed to bleed (FIinTIC): A multicentre, double-blind, placebo-controlled, randomised pilot study. 10/29/2020
Preclinical evaluation of a next-generation, subcutaneously administered, coagulation factor IX variant, dalcinonacog alfa. 10/29/2020
Gastrointestinal bleeding from angiodysplasia in von Willebrand disease: improved diagnosis and outcome prediction using videocapsule on top of conventional endoscopy. 10/29/2020
Pseudotumor of hemophilia of the thumb. 10/27/2020
Radical Cystectomy with Ileal Neobladder in a patient with Hemophilia! A case report. 10/27/2020
Long-Term Antithrombotic Treatments Prescribed for Cardiovascular Diseases in Patients with Hemophilia: Results from the French Registry. 10/27/2020
Patient satisfaction with US Hemophilia Treatment Center Care, Teams and Services: The First National Survey. 10/24/2020
Management of patients with severe haemophilia a without inhibitors on prophylaxis with emicizumab: AICE recommendations with focus on emergency in collaboration with SIBioC, SIMEU, SIMEUP, SIPMeL and SISET. 10/24/2020
Combined intra-articular injections of hyaluronic acid and platelet-rich plasma for the treatment of haemophilic arthropathy: A case series study. 10/24/2020
Challenges and key lessons from the design and implementation of an international haemophilia registry supported by a pharmaceutical company. 10/24/2020
The effectiveness of manual therapy in addition to passive stretching exercises in the treatment of patients with haemophilic knee arthropathy: A randomized, single-blind clinical trial. 10/24/2020
Imaging of Arthropathy in Boys With Hemophilia in China 10/23/2020

Factors Involved in the Development of Inhibitory Antibodies in Patients with Hemophilia in Colombia: A Case-Control Study. 10/23/2020
Cardiac surgery in patients with Hemophilia:is it safe? 10/22/2020
Hemophilia: A Review of Perioperative Management for Cardiac Surgery. 10/22/2020
Quality of electronic treatment records and adherence to prophylaxis in haemophilia and von Willebrand disease: Systematic assessments from an electronic diary. 10/22/2020
Disease burden and remaining unmet need in patients with haemophilia A treated with primary prophylaxis. 10/22/2020
Pharmacokinetics and Pharmacodynamics of Emicizumab in Persons with Hemophilia A with Factor VIII Inhibitors: HAVEN 1 Study. 10/22/2020
Managing Preoperative Hemostasis in Patients with Inherited and Acquired Bleeding Disorders. 10/19/2020
Clinical, pharmacokinetic and economic analysis of the first switch to an extended half-life factor IX (albutrepenonacog alfa, rFIX-FP) in Spain. 10/19/2020
Evaluating international Haemophilia Joint Health Score (HJHS) results combined with expert opinion: Options for a shorter HJHS. 10/19/2020
2020 Clinical Trials Update: Innovations in Hemophilia Therapy. 10/19/2020
Bleeding severity in patients with rare bleeding disorders: real-life data from the RBiN study. 10/19/2020
BAX 335 hemophilia B gene therapy clinical trial results – potential impact of CpG sequences on gene expression. 10/19/2020
Gait Analysis in Moderate Hemophiliac Patients (AQM-Hemophile) 10/19/2020
Pulsed Electromagentic Field in Haemophilia 10/19/2020
A Pharmacokinetic and Clotting Activity Study of FVIII-PEGLip 10/19/2020
iT-based Sports Therapy Application in Haemophilia 10/14/2020
[Haemophilic ankle arthropathy : case reports and review of the literature]. 10/14/2020
Undiagnosed Acquired Hemophilia A: Presenting as Recurrent Gastrointestinal Bleeding. 10/9/2020
Patient Blood Management for Neonates and Children Undergoing Cardiac Surgery: 2019 NATA Guidelines. 10/9/2020
Efficacy and Safety Evaluation of B-Domain Deleted Recombinant Porcine Factor VIII (rpFVIII, TAK-672), in Japanese Participants With Acquired Hemophilia A (AHA) 10/8/2020
Thrombophilia testing in patients with portal vein thrombosis. 10/8/2020
Once-A-Day Prophylaxis for Youth and Young Adults With Severe Hemophilia A 10/7/2020
Joint health and treatment modalities in Nordic patients with moderate haemophilia A and B – The MoHem study. 10/7/2020
Endovascular Management of Hemarthrosis in Patients with Bleeding Diatheses: Systematic Review. 10/6/2020
ST-Segment Elevation Myocardial Infarction (STEMI) and Pulmonary Embolism in a Hemophilia A Patient Receiving Emicizumab and recombinant Activated Factor VII. 10/6/2020
Novel treatment of combined factor V and factor VIII deficiency with Factor Eight Inhibitor Bypass Activity. 10/6/2020
Robotic mitral valve repair in a type B hemophiliac. 10/6/2020
Real-world data demonstrate improved bleed control and extended dosing intervals for patients with haemophilia B after switching to recombinant factor IX Fc fusion protein (rFIXFc) for up to 5 years. 10/5/2020
Feasibility, safety and muscle activity during flywheel vs traditional strength training in adult patients with severe haemophilia. 10/5/2020
Modelling future usage and cost of factor and emicizumab to treat haemophilia A for the US Western States Region IX haemophilia treatment centres. 10/5/2020
3D gait analysis, haemophilia joint health score, leg muscle laterality and biomarkers of joint damage: A cross-sectional comparative assessment of haemophilic arthropathy. 10/4/2020
Fibrinogen concentrates in hereditary fibrinogen disorders: Past, present and future. 10/2/2020
Sleeve gastrectomy in haemophilia type A: Reducing the costs of prophylaxis. 10/2/2020
Clinical application of Web Accessible Population Pharmacokinetic Service-Hemophilia (WAPPS-Hemo): Patterns of blood sampling and patient characteristics among clinician users. 10/2/2020
Bleeding assessment in haemophilia carriers-High rates of bleeding after surgical abortion and intrauterine device placement: A multicentre study in China. 10/2/2020
Emicizumab prophylaxis in patients with haemophilia A with and without inhibitors. 10/2/2020
Rotational thromboelastometry can predict the probability of bleeding events in a translational rat model of haemophilia A following gene-based FVIIa prophylaxis. 10/2/2020
Positive emotions despite substantial burden: The alchemy of haemophilia caregiving. 10/2/2020
von Willebrand Disease and other hereditary haemostatic factor deficiencies in women with a history of postpartum haemorrhage. 10/2/2020
[Origin and nature of the neutralizing immune response against therapeutic factor VIII]. 10/2/2020
Abnormal bleeding phenotype for mild haemophilia B patients with the p.Ile112Thr variation on the gene for factor IX. 10/1/2020
Acupuncture as a therapeutic resource for treatment of chronic pain in people with haemophilia. 10/1/2020
Cross-reacting recombinant porcine FVIII inhibitors in patients with acquired haemophilia A. 10/1/2020
Development of a Self-Assessment Tool for the Nontechnical Skills of Hemophilia Teams. 9/30/2020
A Delphi study to establish consensus on a definition of major bleeding in adult trauma. 9/29/2020
CD4+ T cells engineered with FVIII-CAR and murine Foxp3 suppress anti-factor VIII immune responses in hemophilia a mice. 9/29/2020
Serpins, New Therapeutic Targets for Hemophilia. 9/29/2020
Hemlibra in Mild Hemophilia A 9/28/2020
“Everything Was Blood When it Comes to Me”: Understanding the Lived Experiences of Women with Inherited Bleeding Disorders. 9/28/2020
Pharmacodynamic monitoring of factor VIII replacement therapy in hemophilia A: combining thrombin and plasmin generation. 9/28/2020
Position of the French Working Group on Perioperative Haemostasis (GIHP) on viscoelastic tests: What role for which indication in bleeding situations? 9/26/2020
Direct comparison of two extended half-life PEGylated recombinant FVIII products: a randomized, crossover pharmacokinetic study in patients with severe hemophilia A. 9/26/2020
Treatment of acquired haemophilia A (AHA): a balancing act. Results from a 27-year Dutch cohort study. 9/26/2020
A Pre-conditioning Strategy to Augment Retention and Engraftment Rate of Donor Cells during Hepatocyte Transplantation. 9/26/2020
Weight-based Dosing in Hemophilia A 9/25/2020
A Post Approval Commitment Study to Gain More Information on How Safe and Effective KOVALTRY is in Chinese Children, Adolescents /Adults With Severe Hemophilia A 9/25/2020
Surgery-associated acquired hemophilia A: a report of 2 cases and review of literature. 9/25/2020
A systematic review evaluating the efficacy and factor consumption of long-acting recombinant factor VIII products for the prophylactic treatment of hemophilia A. 9/25/2020
SAFE Study: Safety of aPCC Following Emicizumab Prophylaxis 9/24/2020
Evaluation of a Recombinant Factor IX Product, APVO101, in Previously-Treated Pediatric Patients With Hemophilia B 9/24/2020
Therapeutic Exercise in Patients With Hemophilia 9/24/2020
Management of bleeding and procedures in patients on antiplatelet therapy. 9/24/2020
Maternal and neonatal bleeding complications in relation to peripartum management in women with Von Willebrand disease: A systematic review. 9/24/2020
Adalimumab-associated Acquired Hemophilia in a Patient with Scleritis. 9/24/2020
Gene Therapy for Hemophilia: Are Expectations Matching Reality? 9/24/2020
Mechanism for enhanced transduction of hematopoietic cells by recombinant adeno-associated virus serotype 6 vectors. 9/23/2020
Gene Therapy for Hemophilia: Facts and Quandaries in the 21st Century. 9/22/2020
Light and shadows of the new therapies for haemophilia treatment in the COVID-19 era. 9/22/2020
Bullous pemphigoid is a common associated disorder with acquired haemophilia A. 9/20/2020
Determinants of Quality of Life in Children and Adolescents With Hemophilia in Kabul, Afghanistan: First Report. 9/19/2020
Intronic regions of the human coagulation factor VIII gene harboring transcription factor binding sites with a strong bias towards the short-interspersed elements. 9/19/2020
Safety and Effectiveness of Progressive Moderate-to-Vigorous Intensity Elastic Resistance Training on Physical Function and Pain in People With Hemophilia. 9/18/2020
Long-term safety and efficacy of N8-GP in previously treated pediatric patients with hemophilia A: Final results from pathfinder5. 9/18/2020
High prevalence of overweight/obesity in adult persons with hemophilia in Utah and a review of the literature. 9/18/2020
Outpatient central venous access device insertion in very young children with severe haemophilia. 9/18/2020
Treatment preferences in people with haemophilia A or caregivers of people with haemophilia A: A discrete choice experiment. 9/17/2020
Platelet-Rich Plasma Intra-Articular Injection in Treating Hemophilic Arthropathy 9/17/2020
The societal burden of haemophilia A. I – A snapshot of haemophilia A in Australia and beyond. 9/17/2020
The societal burden of haemophilia A. II – The cost of moderate and severe haemophilia A in Australia. 9/17/2020
The societal burden of haemophilia A. III – The potential impact of emicizumab on costs of haemophilia A in Australia. 9/17/2020
Impact of COVID-19 pandemic on mental health of patients with inherited bleeding disorders in Germany. 9/17/2020
History of the West of Scotland Haemophilia Centre, Glasgow, 1950-2019. 9/17/2020
Optimizing the management of patients with haemophilia A and inhibitors in the era of emicizumab: Recommendations from a German expert panel. 9/17/2020
Functionalized lipid-like nanoparticles for in vivo mRNA delivery and base editing. 9/17/2020
Patient and caregiver preferences for haemophilia A treatments: A discrete choice experiment. 9/17/2020
Factor VIII inhibitor development in Egyptian hemophilia patients: does intron 22 inversion mutation play a role? 9/16/2020
Activated Coagulation Time and Hepcon Protamine Titration Device to Manage Unfractionated Heparin During Cardiopulmonary Bypass in a Hemophilia A Patient on Emicizumab. 9/16/2020
COVID-19 in benign hematology: emerging challenges and special considerations for healthcare professionals. 9/16/2020
A Study to Assess Pharmacokinetics and Pharmacodynamics Following Administration of BAY1093884 in Patients With Severe Hemophilia 9/16/2020
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Emicizumab Given Every 4 Weeks in Participants With Hemophilia A 9/16/2020
Study of Coagulation Factor VIIa Marzeptacog Alfa (Activated) in Subjects With Inherited Bleeding Disorders 9/15/2020
Movement Visualization in Pain Management in Patients With Hemophilic Arthropathy. 9/15/2020
Treatment patterns and bleeding outcomes in persons with severe hemophilia A and B in a real-world setting. 9/13/2020
A Haemophilic Dengue Patient with Pleural Effusion and Earache. 9/12/2020
Validation of a liquid chromatography tandem mass spectrometry method for the simultaneous determination of hydroxychloroquine and metabolites in human whole blood. 9/12/2020
Activity of Transgene-Produced B-Domain Deleted Factor VIII in Human Plasma Following AAV5 Gene Therapy. 9/12/2020
Acquired Haemophilia A in Association with Influenza A and Urinary Tract Infection. 9/12/2020
Gene therapy to cure haemophilia: Is robust scientific inquiry the missing factor? 9/11/2020
Acquired Combined Factor Deficiency: Case Report. 9/10/2020
BIVV001 Fusion Protein as Factor VIII Replacement Therapy for Hemophilia A. 9/10/2020

Treatment of Hemophilia – More Amazing Progress. 9/10/2020
Emicizumab Augments Thrombus Formation in Whole Blood from Patients with Hemophilia A under High Shear Flow Conditions. 9/10/2020
Study of Coagulation Faction VIIa Variant Marzeptacog Alfa (Activated) in Adult Subjects With Hemophilia 9/9/2020
Moroctocog Alfa (AF-CC) for Prophylaxis and Treatment of Bleeding Episodes in Previously Treated Hemophilia A Patients 9/9/2020
Safety & Efficacy of Encapsulated Allogeneic FVIII Cell Therapy in Haemophilia A 9/9/2020
PF-06741086 Long-term Treatment in Severe Hemophilia 9/9/2020
Is placental blood a reliable source for the evaluation of neonatal hemostasis at birth? 9/9/2020
Acquired haemophilia a secondary to multiple myeloma: management of a patient with a mechanical mitral valve. 9/9/2020
A case of arthroscopic ankle arthrodesis for hemophilic arthropathy of the bilateral ankles. 9/9/2020
Thrombin generation assay modifications needed for its application to monitoring of replacement therapy for haemophilia. 9/9/2020
Deep Brain Stimulation Surgery for Essential Tremor in a Patient with Type A Hemophilia. 9/8/2020
Cost-utility analysis of emicizumab prophylaxis in haemophilia A patients with factor VIII inhibitors in Korea. 9/8/2020
Nonacog Alfa Prophylaxis And Treatment Of Bleeding Episodes In Previously Treated Patients With Hemophelia B 9/8/2020
Study of rFVIIIFc for ITI in Haemophilia A Patients With Inhibitors Who Have Failed Previous ITI Therapies 9/8/2020
Initiation of emicizumab prophylaxis in an infant with haemophilia A and subdural haemorrhage. 9/8/2020
Clinical utility of sample preheat treatment in a modified Nijmegen-Bethesda assay (mNBA) for inhibitor monitoring in congenital and acquired haemophilia A: A single-centre four-year experience. 9/8/2020
Management of haemophilia patients in the COVID-19 pandemic: Experience in Wuhan and Tianjin, two differently affected cities in China. 9/8/2020
A non-viral genome editing platform for site-specific insertion of large transgenes. 9/5/2020
Total Knee Arthroplasty in Patients with Hemophilia: What Do We Know? 9/5/2020
Emerging benefits of Fc fusion technology in the context of recombinant factor VIII replacement therapy. 9/5/2020
Mitigation of T-cell dependent immunogenicity by reengineering factor VIIa analogue. 9/5/2020
Evaluation of CDC’s Hemophilia Surveillance Program – Universal Data Collection (1998-2011) and Community Counts (2011-2019), United States. 9/5/2020
Health-related quality of life of moderate and severe haemophilia patients: Results of the haemophilia-specific quality of life index in Korea. 9/5/2020
Does Hemophilia Increase Risk of Adverse Outcomes Following Total Hip and Knee Arthroplasty? A Propensity Score-Matched Analysis of a Nationwide, Population-Based Study. 9/3/2020
Costs of gastrointestinal bleeding events in atrial fibrillation: a UK Clinical Practice Research Datalink study. 9/3/2020
EMG, Rate of Perceived Exertion, Pain, Tolerability and Possible Adverse Effects of a Knee Extensor Exercise with Progressive Elastic Resistance in Patients with Severe Haemophilia. 9/3/2020
Recombinant VWF Fragments Improve Bioavailability of Subcutaneous Factor VIII in Hemophilia A Mice. 9/3/2020
The factor VIII treatment history of non-severe hemophilia A. 9/3/2020
Safety, Immunogenicity, and Hemostatic Efficacy of Nonacog Gamma in Patients With Severe or Moderately Severe Hemophilia B: A Continuation Study. 9/1/2020
Functionality and range of motion in patients with hemophilic ankle arthropathy treated with fascial therapy. A randomized clinical trial. 8/31/2020
Successful intraosseous factor VIII application in a haemophilic emergency. 8/30/2020
A Phase III Study on the Safety, Pharmacokinetics and Efficacy of Coagulation Factor VIIa 8/28/2020
Targeting Translation Termination Machinery with Antisense Oligonucleotides for Diseases Caused by Nonsense Mutations. 8/28/2020
The role of the physiotherapist in the management of people with haemophilia: defining the new normal. 8/28/2020
BioMarin Defends Up-to-$3M List Price of Hemophilia A Gene Therapy. 8/28/2020
Summary of the WHO hearing on the development of product-specific reference materials for coagulation factor VIII and factor IX products. 8/28/2020
Recombinant porcine factor VIII use in bleed treatment in non-severe haemophilia A inhibitor patients: Dosing strategies and efficacy. 8/26/2020
Illness cognitions associated with health-related quality of life in young adult men with haemophilia. 8/26/2020
Improving access to hemophilia care in sub-Saharan Africa by capacity building. 8/25/2020
Determinants of health-related quality of life: a cross-sectional investigation in physician-managed anticoagulated patients using vitamin K antagonists. 8/25/2020
Modeling to Predict Factor VIII Levels Associated with Zero Bleeds in Patients with Severe Hemophilia A Initiated on Tertiary Prophylaxis. 8/25/2020
A Novel, Enriched Population Pharmacokinetic Model for Recombinant Factor VIII-Fc Fusion Protein Concentrate in Hemophilia A Patients. 8/25/2020
[Clinical effect of one-stage total knee arthroplasty for knee osteoarthritis with femoral extra-articular deformity]. 8/25/2020
European principles of inhibitor management in patients with haemophilia: implications of new treatment options. 8/25/2020
Viral vector manufacturing: quality attributes of rAAV used in clinical development. 8/25/2020
Factor VIII: Perspectives on Immunogenicity and Tolerogenic Strategies for Hemophilia A Patients. 8/25/2020
Postpartum bleeding in women with inherited bleeding disorders: a matched cohort study. 8/25/2020
[Human cells for therapeutics purpose: State of the art]. 8/25/2020
A Real-World Analysis of Commonly Prescribed FVIII Products Based on U.S. Medical Charts: Consumption and Bleeding Outcomes in Hemophilia A Patients. 8/22/2020
Management of previously untreated patients with severe haemophilia A preferentially treated with recombinant factor VIII products: Two French centres’ real-life experience. 8/21/2020
Chronic pain in patients with hemophilia: is it preventable? 8/21/2020
Are Iranian patients with von Willebrand disease type 2N properly differentiated from hemophilia A and do they receive appropriate treatment? 8/21/2020
Safety and Efficacy of BAY94-9027 in Previously Treated Male Children With Haemophilia A 8/21/2020
StatPearls 8/19/2020
Tissue distribution of rIX-FP after intravenous application to rodents. 8/19/2020
Assessment of Self-Image With the Offer Self-Image Questionnaire in Adolescents With Hemophilia: A Single-Center Experience. 8/18/2020
Generation of a gene edited hemophilia A patient-derived iPSC cell line, YCMi001-B-1, by targeted insertion of coagulation factor FVIII using CRISPR/Cas9. 8/18/2020
Tailoring haemophilia A prophylaxis with BAY 81-8973: A case series. 8/18/2020
Prevalence of FVIII Inhibitors Among Children with Hemophilia A: Experience at the Jordanian Royal Medical Services. 8/18/2020
Chronic pain in patients with hemophilia: is it preventable? 8/18/2020
Are Iranian patients with von Willebrand disease type 2N properly differentiated from hemophilia A and do they receive appropriate treatment? 8/17/2020
How I manage pregnancy in carriers of hemophilia and patients with von Willebrand disease. 8/17/2020
Beliefs and Values About Gene Therapy and In-Utero Gene Editing in Patients with Hemophilia and Their Relatives. 8/15/2020
Zeolite-fibrin clot composite as a haemostatic agent for haemophilia A. 8/14/2020
Plasma Exchange as an Initial Treatment for Severe Bleeding Induced by Acquired Factor V Deficiency: A Case Report and Mini Literature Review. 8/14/2020
Pulmonary Embolism in Acquired Hemophilia A: A Rare Complication With Factor VIII Inhibitor Bypassing Activity Therapy. 8/14/2020
Acquired Haemophilia Associated with Urticarial Vasculitis. 8/14/2020
An Open Label Study to Determine the Safety and Efficacy of Replacement Factor VIII Protein (Known as rFVIIIFc) in Previously Untreated Males With Severe Hemophilia A 8/13/2020
Study to Evaluate the Efficacy and Safety of PF-07055480 in Moderately Severe to Severe Hemophilia A Adults 8/12/2020
Muscle strength and joint health in children with hemophilia: a cross-sectional study. 8/12/2020
Gene therapy for hemophilia: anticipating the unexpected. 8/12/2020
Clinical findings in a patient with haemophilia A affected by COVID-19. 8/11/2020
CRISPR-Cas9-Mediated In Vivo Gene Integration at the Albumin Locus Recovers Hemostasis in Neonatal and Adult Hemophilia B Mice. 8/11/2020
Ready for Repair? Gene Editing Enters the Clinic for the Treatment of Human Disease. 8/11/2020
Induction of ER Stress by an AAV5 BDD FVIII Construct Is Dependent on the Strength of the Hepatic-Specific Promoter. 8/11/2020
Outcomes in children with hemophilia A with inhibitors: Results from a noninterventional study. 8/11/2020
Evaluating the Haemostatic Effect of NNC 0129-0000-1003 During Surgical Procedures in Subjects With Haemophilia A. 8/10/2020
Gene Therapy for Hemophilia A: Where We Stand. 8/10/2020
Bleeder With a Clot: Thrombosis Following Treatment of Bleeding in a Child With Severe Hemophilia B. 8/10/2020
Patient Preferences in the Treatment of Hemophilia A: A Best-Worst Scaling Case 3 Analysis. 8/9/2020
Emicizumab for the treatment of acquired hemophilia A. 8/9/2020
[Acquired hemophilia A]. 8/8/2020
Rituximab for treating inhibitors in people with inherited severe hemophilia. 8/8/2020
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Prophylactic Emicizumab Versus no Prophylaxis in Hemophilia A Participants With Inhibitors 8/6/2020
Improvement in Hepatic Fibrosis Biomarkers Associated With Chemokine Receptor Inactivation Through Mutation or Therapeutic Blockade. 8/5/2020
Haemophilia care in Europe: Past progress and future promise. 8/5/2020
A Multinational, Open-Label, Non-Controlled Trial on Safety, Efficacy and Pharmacokinetics of NNC 0129-0000-1003 in Previously Treated Paediatric Patients With Severe Haemophilia A 8/4/2020
Haemostatic efficacy of single-dose factor administration in neonates with severe haemophilia undergoing circumcision. 8/4/2020
The evolving landscape of gene therapy for congenital haemophilia: An unprecedented, problematic but promising opportunity for worldwide clinical studies. 8/3/2020
Early wound complications after orthopaedic surgery for haemophilia: What can we do more. 8/3/2020
Depressive symptoms and adherence to prophylaxis in patients with haemophilia from Croatia and Slovenia. 8/3/2020
Self-Myofascial Release Intervention and Mobile App in Patients With Hemophilic Ankle Arthropathy: Protocol for a Randomized Controlled Trial. 8/1/2020
COVID-19: Coagulopathy, Risk of Thrombosis, and the Rationale for Anticoagulation. 8/1/2020
Therapeutic choices in persons with haemophilia at the time of COVID-19. 8/1/2020
[Pain management in rare diseases]. 8/1/2020
Study to Determine the Safety and Efficacy of rFIXFc in Previously Untreated Males With Severe Hemophilia B 7/31/2020
Trial of AAV5-hFIX in Severe or Moderately Severe Hemophilia B 7/31/2020
Gene Therapy for Chinese Hemophilia B 7/31/2020
Ex vivo editing of human hematopoietic stem cells for erythroid expression of therapeutic proteins. 7/31/2020
Living donor domino liver transplantation in a hepatitis C virus/human immunodeficiency virus-coinfected hemophilia patient: a case report. 7/31/2020

Growth hormone deficiency as a complication of haemophilia – a case report and literature data. 7/31/2020
Immunotolerance induction effectivity in hemophilia A children and neutralizing alloantibodies. 7/31/2020
Hypermethioninemia Leads to Fatal Bleeding and Increased Mortality in a Transgenic I278T Mouse Model of Homocystinuria. 7/30/2020
Complications of hemophilia in the elbow: current management. 7/30/2020
Perioperative Management of Hemophilia A Patients Undergoing Cardiac Surgery: A Literature Review of Published Cases. 7/30/2020
Dose-Escalation Study Of A Self Complementary Adeno-Associated Viral Vector For Gene Transfer in Hemophilia B 7/30/2020
The Evolution of Hemophilia Care: Clinical and Laboratory Advances, Opportunities, and Challenges. 7/30/2020
Common Genetic Variants in ABO and CLEC4M Modulate the Pharmacokinetics of Recombinant FVIII in Severe Hemophilia A Patients. 7/30/2020
Hemophilia A and B: molecular and clinical similarities and differences. 7/29/2020
Pilot trial of semi-automated medical note writing using lexeme hypotheses. 7/29/2020
Phase 3 Study of Coagulation Factor VIIa Marzeptacog Alfa (Activated) in Subjects With Hemophilia A or B 7/28/2020
Life expectancy and cause of death in individuals with haemophilia A and B in Norway, 1986-2018. 7/28/2020
Evolution of clotting factor concentrates prescriptions and impact of recommendations of prophylaxis in children with haemophilia. 7/28/2020
Non-Compartment and Compartmental Pharmacokinetics, Efficacy, and Safety of Kedrion FIX concentrate. 7/28/2020
The one-stage assay or chromogenic assay to monitor baseline factor VIII levels and desmopressin effect in non-severe haemophilia A: Superiority or non-inferiority? 7/28/2020
Acquired Hemophilia A: A Potentially Fatal Bleeding Disorder. 7/28/2020
Pfizer and Sangamo Hemophilia A Gene Therapy Aces First Clinical Test. 7/28/2020
Origins, Development, Current Challenges and Future Directions with Activated Prothrombin Complex Concentrate for the Treatment of Patients with Congenital Haemophilia with Inhibitors. 7/28/2020
Bridging the Missing Link with Emicizumab: A Bispecific Antibody for Treatment of Hemophilia A. 7/28/2020
Synergistic Effect of Bypassing Agents and Sequence Identical Analogue of Emicizumab and Fibrin Clot Structure in the In Vitro Model of Hemophilia A. 7/27/2020
Safety and Efficacy of Nonacog Beta Pegol (N9-GP) in Previously Untreated Patients With Haemophilia B 7/27/2020
Efficacy and Safety of Turoctocog Alfa for Prophylaxis and Treatment of Bleeding Episodes in Previously Treated Chinese Patients With Haemophilia A 7/27/2020
Susoctocog-alfa (Obizur®) in the treatment of nine elderly patients with acquired haemophilia A: an Italian multicentre real world experience. 7/24/2020
Acquired haemophilia A after alemtuzumab therapy. 7/24/2020
Risk of deep venous thrombosis after total knee arthroplasty in patients with haemophilia A. 7/24/2020
Clinical characteristics and surgical treatment of haemophilic pseudotumor: A retrospective analysis of thirty-four patients. 7/24/2020
Successful correction of factor V deficiency of patient-derived iPSCs by CRISPR/Cas9-mediated gene editing. 7/24/2020
Severe haemophilia A children on low-dose tertiary prophylaxis showed less joint deterioration and better maintenance of functional independence than children on on-demand treatment: A 6-year follow-up study. 7/24/2020
Adherence to prophylaxis in adult patients with severe haemophilia A. 7/24/2020
Nonsevere hemophilia A: often overlooked, but not forgotten. 7/24/2020
Prophylaxis Using a Mixture of Plasma-Derived Activated Factor VII and Factor X (pdFVIIa/FX) in a Patient with Hemophilia B Complicated by Inhibitors and Allergy to Factor IX Concentrates: A Case Report. 7/24/2020
The first case of acquired hemophilia A associated with SARS-CoV-2 infection. 7/23/2020
A Novel Quantitative Method for Analyzing Desmopressin in Human Plasma using Liquid Chromatography-Tandem Mass Spectrometry. 7/23/2020
Single-Arm Study To Evaluate The Efficacy and Safety of Valoctocogene Roxaparvovec in Hemophilia A Patients 7/23/2020
Single-Arm Study To Evaluate The Efficacy and Safety of Valoctocogene Roxaparvovec in Hemophilia A Patients at a Dose of 4E13 vg/kg 7/23/2020
Recombinant vs plasma-derived von Willebrand factor to prevent postpartum hemorrhage in von Willebrand disease. 7/22/2020
Emicizumab PUPs and Nuwiq ITI Study 7/21/2020
Evaluation of gum health status in hemophilia patients in Birjand (a case-control study). 7/21/2020
Illustrated State-of-the-Art Capsules of the ISTH 2020 Congress. 7/21/2020
Development of inhibitors in hemophilia A: An illustrated review. 7/21/2020
N-Methyl-3,4-methylendioxymethamphetamine (MDMA)-related coagulopathy and rhabdomyolysis: A case series and literature review. 7/21/2020
Perioperative anaesthesia and coagulation management of haemophilia patients receiving total hip and knee replacement arthroplasty: Experience from a case series. 7/21/2020
Emicizumab for infants and children with haemophilia A. 7/21/2020
Gene Therapy Study in Severe Haemophilia A Patients 7/20/2020
Acquired haemophilia A, concomitant acute myocardial infarction and urgent major surgery: How to successfully treat a critical patient with rpFVIII (Obizur®). 7/20/2020
Chains of Iron in UBC-HCT: Comment on “Iron Overload is Associated with Delayed Engraftment and Increased Non-Relapse Mortality in Recipients of Umbilical Cord Blood Hematopoietic Cell Transplantation” by Al Malki et al. 2020. 7/19/2020
How haemophilia A impacts severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2) treatment: a case report. 7/18/2020
A Phase 3, Open-label Interventional Study of an Intravenous Recombinant Coagulation Factor VIII Fc-von Willebrand Factor-XTEN Fusion Protein, BIVV001, in Patients With Severe Hemophilia A (XTEND-1) 7/17/2020
B Cell Depletion Eliminates FVIII Memory B Cells and Enhances AAV8-coF8 Immune Tolerance Induction When Combined With Rapamycin. 7/17/2020
Acquired Haemophilia A: An Intriguing Disease. 7/17/2020
A Study to Evaluate the Safest Dose Range for FEIBA in Hemophilia A Patients With Inhibitors on Emicizumab 7/16/2020
Unravelling the knowledge, beliefs, behaviours and concerns of Persons with Haemophilia and their carriers in Senegal. 7/16/2020
Haemophilia care in China: Achievements in the past decade. 7/16/2020
Prognostic factors of radiosynovectomy in haemophilia patients with inhibitors: Survival analysis in a 19-year period. 7/16/2020
Emicizumab treatment: Impact on coagulation tests and biological monitoring of haemostasis according to clinical situations (BIMHO group proposals). 7/16/2020
Advances in Alpha-1 Antitrypsin Gene Therapy. 7/16/2020
Drug levels and bleeding complications in atrial fibrillation patients treated with direct oral anticoagulants. 7/15/2020
Comparative pharmacokinetics of two extended half-life FVIII concentrates (Eloctate and Adynovate) in adolescents with hemophilia A: Is there a difference? 7/15/2020
Functional polymorphisms in the LDLR and pharmacokinetics of Factor VIII concentrates. 7/15/2020
Prophylactic administration of glycoPEGylated factor IX provides protection and joint outcome superior to recombinant factor IX after induced joint bleeding. 7/15/2020
Novel Insights and New Developments Regarding Coagulation Revealed by Studies of the Anti-Factor IXa (Activated Factor IX)/Factor X Bispecific Antibody, Emicizumab. 7/15/2020
Evolution of Haemophilia Care in Europe: 10 years of the principles of care. 7/15/2020
Advances in gene therapy for hemophilia. 7/15/2020
Variation of rs3754689 at lactase gene and inhibitors in admixed Brazilian patients with hemophilia A. 7/14/2020
Musculo-skeletal problems of the hand in haemophilia. 7/14/2020
Emicizumab treatment and monitoring in a paediatric cohort: real-world data. 7/14/2020
Development of a Clinical Candidate AAV3 Vector for Gene Therapy of Hemophilia B. 7/14/2020
Experience of Immune Tolerance Induction Therapy for Hemophilia A Patients with Inhibitors from a Single Center in India. 7/11/2020
Clinical Trial Comparing a Biosimilar Eptacog Alfa With Novoseven, in Patients With Hemophilia With Inhibitors 7/10/2020
Impact on French Physician’s Haemophilia Treatment Management Decision Based on Systematic Joint Examination 7/10/2020
StatPearls 7/10/2020
HIV-associated and idiopathic-acquired haemophilia A: A single-centre case series from Cape Town, South Africa. 7/10/2020
A Study to Evaluate the Efficacy and Safety of Factor IX Gene Therapy With PF-06838435 in Adult Males With Moderately Severe to Severe Hemophilia B 7/9/2020
A Clinical Trial to Evaluate Prophylactic Emicizumab Versus no Prophylaxis in Hemophilia A Participants Without Inhibitors 7/9/2020
A novel simultaneous clot-fibrinolysis waveform analysis for assessing fibrin formation and clot lysis in haemorrhagic disorders. 7/9/2020
Regulatory-Compliant Validation of a Highly Sensitive qPCR for Biodistribution Assessment of Hemophilia A Patient Cells. 7/9/2020
Development of AAV Variants with Human Hepatocyte Tropism and Neutralizing Antibody Escape Capacity. 7/9/2020
Hemophilia gene therapy-New country initiatives. 7/9/2020
The Hemophilia Inhibitor Eradication Trial 7/8/2020
The Hemophilia Inhibitor Prevention Trial 7/8/2020
Comparison between coagulation factor VIII quantified with one-stage activity assay and with mass spectrometry in haemophilia A patients: Proof of principle. 7/8/2020
Evaluation of Safety Following Immune Tolerance Induction Treatment With Turoctocog Alfa in Patients With Haemophilia A Following Inhibitor Development in NN7170-4213 Trial 7/7/2020
Study of Next-Generation Recombinant Factor IX Variant in Adult Subjects With Hemophilia B 7/7/2020
[Successful treatment by switching from activated prothrombin complex concentrate to emicizumab therapy in a hemophilia A patient with inhibitors]. 7/7/2020
Absence of bleeding upon dual antiplatelet therapy in a patient with a immune GPVI deficiency. 7/7/2020
Inhibitor development in previously untreated patients with severe haemophilia: A comparison of included patients and outcomes between a clinical study and a registry-based study. 7/7/2020
Efficacy and Safety of half-dose desmopressin for bleeding prophylaxis in bleeding disorder patients undergoing predominantly low to moderate risk invasive procedures. 7/7/2020
The Effect of Age on von Willebrand Factor and Bleeding Symptoms in von Willebrand Disease. 7/7/2020
Reduced-intensity, risk factor-stratified immunosuppression for acquired hemophilia A: single-center observational study. 7/6/2020
Initial joint bleed volume in a delayed on-demand treatment setup correlates with subsequent synovial changes in hemophilic mice. 7/3/2020
Feasibility of a Blended Therapy Approach 7/2/2020
RIXUBIS PMS India (RIXUBIS PMS) 7/2/2020
A Research Study Looking at How a Factor VIII Medicine Called Turoctocog Alfa Pegol (N8-GP) Works in People With Haemophilia A 7/2/2020
A Study to Evaluate Efficacy of rFVIIIFc for Immune Tolerance Induction (ITI) in Severe Hemophilia A Participants With Inhibitors Undergoing the First ITI Treatment (verITI-8 Study) 7/2/2020
An Open Label Study to Determine the Safety and Efficacy of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection in Adolescent and Adult Patients With Hemophilia A. 7/2/2020
Safety and Efficacy of Turoctocog Alfa in the Prevention and Treatment of Bleeding Episodes in Previously Treated Patients from China with Severe Hemophilia A: Results from the Guardian 7 Trial. 7/2/2020
Inhibitors-Recent insights. 7/2/2020
A Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of Emicizumab in Participants With Mild or Moderate Hemophilia A Without FVIII Inhibitors 7/1/2020
Platelet-Targeted FVIII Gene Therapy Restores Hemostasis and Induces Immune Tolerance for Hemophilia A. 7/1/2020
Dose-Ranging Study of Recombinant AAV2/6 Human Factor 8 Gene Therapy SB-525 in Subjects With Severe Hemophilia A 7/1/2020